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Summary 
Over the years biomedical research was focused on the development of new 
anticancer agents able to selectively target cancer cells at low concentration 
efficacy. Based on the idea that oncogenes and tumour suppressor genes are a 
critical force in the malignant transformation of cells, research efforts have focused 
on developing drugs that directly target these genes. In this context my PhD thesis, 
focused on the study of new molecules endowed with antiproliferative activity and 
different mechanisms of action. 
In the first study we focused on B-cell acute lymphoblastic leukaemia (B-ALL), that is 
one of the most common paediatric malignant disorders characterized by an 
accumulation of B-cell blasts reminiscent of normal stages of differentiation and by 
infiltration of various extramedullary sites.  
Excessive cell proliferation induced by aberrant entry into the cell cycle is 
considered an hallmark of cancer. Recent findings have revealed that CDK4/6 and its 
regulatory subunit cyclin D1 are potentially oncogenes and are overexpressed in a 
diverse set of human cancers, including B-cell acute lymphoblastic leukemia (B-ALL). 
Moreover, CDK6 is essential for MLL-rearranged leukemias. These findings suggest 
that CDK4/6 may be effective targets for therapeutic intervention. To test this 
possibility, we have inhibited CDK4 and CDK6 in four cell lines of B-ALL, 
characterized by different genetic rearrangements, using Ribociclib, an orally 
bioavailable, small molecule inhibitor of both CDK4 and CDK6. At low concentration, 
Ribociclib potently inhibit CDK4/6 without induction of apoptosis; therefore, 
standard treatment for newly diagnosed childhood B-ALL patients includes 
glucocorticoids (GC) treatment, but the molecular basis of GC sensitivity and 
resistance remains largely unknown; for this reason we have tested if Ribociclib in 
combination with Dexamethasone, a glucocorticoid that is currently used as 
antitumour agent in the treatment of leukemia, may lead to synergistic killing of 
leukemia cells.  
B-ALL patients that respond poorly to glucocorticoid therapy when diagnosed are 
usually predicted to undergo relapse. Therefore, understanding the biological 
mechanisms underlying this poor responsiveness is crucial for the development of 
more effective therapies. 
In the second study we focused our attention on multidrug resistance (MDR) that is 
one of the most frequent causes of failure of cancer; MDR can lead to the reduction 
of intracellular drug levels and consequent drug insensitivity, often to multiple 
agents. A well-established cause of MDR involves the increased expression of 
members of the ATP binding cassette (ABC) transporter superfamily, many of which 
efflux various chemotherapeutic compounds from cells.  
Recent discoveries have provided clear evidence that cancer stem cells are present 
in several cancerous tissues, such as medulloblastoma, neuroblastoma, colon and 
breast cancers. These cancer stem cells represent only a small percentage of total 
cell populations and efficiently efflux Hoechst dye resulting in the dye-negative 
phenotype, also known as side population (SP) phenotype. Further investigations 
revealed that Hoechst dye efflux is attributable to increased levels of expression of 
the ABC transporters, which are capable of extruding certain chemotherapeutic 
agents, and have been implicated in drug resistance. Several approaches have been 
taken to overcome ABC transportes mediated drug resistance. Recent studies found 
that certain ecdysteroids derivative, such as the most common 20-hydroxyecdysone, 
significantly decrease the resistance of a multi-drug resistant (MDR) murine leukemia 
cell line expressing the human ABCB1 transporter to doxorubicin. This has prompted 
us to study new candidates structures as P-gp inhibitors derived from ecdysone. We 
found that these new synthetic P-gp inhibitors could be promising in overcoming 
multidrug resistance in association with standard chemoterapeutic agents and in 
eradicating the side population portion that is one of the most resistant cell 
population to chemotherapy in solid tumours such as medulloblastoma. 
In the third study we focused our attention on antitubulinic agents because the most 
common features of human cancer are the cell cycle deregulation that leads to hyper 
proliferation pattern. Several therapeutic strategies have been proposed for 
targeting the tubulin polymerization in cancer. Tubulin binding agents constitute an 
important class of compounds with broad activity in both solid and in hematologic 
neoplasia. These agents are believed to block cell division by interfering with the 
function of the mitotic spindle, blocking cells at the metaphase/anaphase junction of 
mitosis. In this work we evaluated the antiproliferative activity, interactions with 
tubulin and cell cycle effects of a new class of simple synthetic inhibitors of tubulin 
polymerization based on the molecular skeleton of 2-alkoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino) thiophene. The results we obtained indicated that compound 4c 
possessed the highest overall potency and displayed high antiproliferative activities 
at submicromolar concentrations; we found that it could induce tumour cell 
apoptosis through reducing the mitochondrial membrane potential and regulating the 
expression of apoptosis-related proteins in tumour cells. 
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1.1. General introduction 
During the mammalian cell cycle, progression through the first gap (G1) phase and 
initiation of DNA synthesis (S) phase is cooperatively regulated by several cyclins and 
their associated cyclin dependent kinase (CDKs) (1). The principal kinases involved 
during G1 phase are CDK4, CDK6 and CDK2 (2). CDK4 and CDK6 form active 
complexes with one of the three D-type cyclins (D1, D2 or D3) while CDK2 associates 
with cyclin E; these complexes promote G1-S transition by phosphorylating 
retinoblastoma tumour suppressor protein (RB). Phosphorylation of RB disables its 
function as transcriptional repressor to allow activation of the E2F-dependent 
transcriptional program, an important mediator of S-phase entry and initiation of 
DNA synthesis (3). 
To prevent abnormal proliferation, assembly of active cyclin D-CDK4/CDK6 
complexes is negatively and strictly regulated by INK4 protein family members p16, 
p15, p18 and p19 and by a second group of protein including p21 and p27 (4).  
In cancer, cell cycle is dysregulated causing excessive cell proliferation that 
promotes tumourigenesis and disease progression. Therefore, dysregulation of cell 
cycle is a hallmark of cancer.  
CDK4/CDK6 are frequently hyperactivated or overexpressed in a wide variety of 
cancers; in particular, it has been found that CDK6 is a direct target of MLL fusion 
protein in MLL-rearranged acute lymphoblastic leukemia (5).  
Based on this, CDK4/CDK6 may be attractive therapeutic targets in childhood acute 
lymphoblastic leukemia. 
1.2 Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is a malignant clonal proliferation of lymphoid 
progenitor cells and it is one of the four main categories of human leukemia; the 
majority of ALLs are of the B-cell type, characterized by an accumulation of blast B-
cells (6). Although ALL can occur at any age, it is more prevalent among children, 
particularly those aged 3–6 years old. Children treated on modern protocols have 
survival rates exceeding 90%. Despite significant advances in treatment, 
approximately 15% to 20% of patients with ALL suffer relapsed disease, the most 
common cause of treatment failure with an overall survival rate of only 30% (7). 
Standard treatment options for newly diagnosed childhood B-ALL patients include 
chemotherapy treatment and, more commonly, a four-drug induction regimen, 
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composed of vincristine, glucocorticoids (Dexamethasone or prednisone), L-
asparaginase, Ara-c (Cytarabine) and either doxorubicin or daunorubicin (8). 
Although glucocorticoids (GC) are the most important drugs used in the treatment of 
ALL for more than 50 years, the molecular basis of GC sensitivity and resistance 
remains largely unknown. Elucidating the molecular mechanisms related to GC 
cytotoxicity is crucial for understanding a major part of treatment success or failure 
in childhood ALL and for the exploration of possibilities to modulate GC resistance 
(9). 
1.3 p16-Cyclin D1-CDK4/CDK6-retinoblastoma axis 
The p16-Cyclin D1-CDK4/CDK6-retinoblastoma (RB) axis critically regulates G1 to S 
phase progression. In response to mitogenic signaling, Cyclin D1-CDK4/CDK6 and 
Cyclin E/CDK2 complexes cooperate to phosphorylate the tumour suppressor 
retinoblastoma protein on multiple serine and threonine residues. These 
phosphorylation events disrupt RB-mediated transcriptional repression and facilitate 
progression into S-phase (10) (Fig.1). 
 
Fig. 1 Overview of p16-Cyclin D-CDK4/CDK6 pathway (11). 
INK4 protein family: p16 
p16 is the principal member of the INK4 family of CDK inhibitors and it is codified by 
a gene localized on chromosome 9p21 within the INK4a/ARF locus, which encodes for 
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two different proteins with different promoters: p16/INK4a and p19/ARF. Both 
proteins have antiproliferative biological activity, and are involved in the 
retinoblastoma protein and p53 pathways, respectively (12). 
The principal function of p16 is the binding to CDK4 and CDK6 inhibiting their 
catalytic activity; in addition, to become functional, CDK4/CDK6 require 
cytoplasmic, post-translational folding in a complex involving heat shock protein 
(HSP) 90, an interaction that is disrupted by p16. The INK4a locus (also known 
as CDKN2a) appears to be inactivated in a wide variety of tumours including 
melanoma, pancreatic adenocarcinoma, glioblastoma, certain leukemias (T-ALL and 
B-cell ALL), non-small cell lung cancer and bladder carcinoma; among mechanisms 
that inactivate p16 in tumour cells, homozygous deletion may predominantly 
contribute to tumourigenesis or disease progression (13;14). Frequency of p16 
deletions in B-cell acute lymphoblastic leukemia is around 20% (15). 
1.3.1 Cyclin D 
Cyclin D (CCND1) promotes cell proliferation as a regulatory partner for CDK4 or 
CDK6. The resulting cyclin D-CDK complexes display two distinct functions: 1-in the 
kinase-dependent function, cyclin D-CDK4/CDK6 complex phosporilates the 
retinoblastoma protein; 2-in the kinase-independent function, D-type cyclins 
physically bind and activate or repress the activity of several transcription factors 
(16). There are three D-type cyclins: cyclin D1, cyclin D2 and cyclin D3; cyclin D2 and 
cyclin D3 proteins are 62% and 51%, respectively, identical to cyclin D1, and 62% 
identical to each other. Of the three D-type cyclins, cyclin D1 is a known oncogene 
which overexpression is predominantly associated with human tumourigenesis and 
cellular metastasis; this overexpression is commonly associated with copy number 
alterations, or more rarely with mutation, or as a consequence of the dysregulation 
of mitogenic signalling (17). 
1.3.2 Cyclin-dependent kinases (CDKs) 
The family of cyclin-dependent kinases (CDKs) contains over 20 members; in 
particular, CDK4/CDK6 are homologous proteins with overlapping functions in the 
initiation of the cell cycle. Unbound CDKs are catalytically inactive but when bound 
to the appropriate D-type cyclins (D1, D2 and D3) the proteins acquire a kinase 
activity, which is necessary to drive progression of the cell cycle. Cyclin D-CDK4/6 
complexes also exert direct regulatory effects on other transcriptional programs to 
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govern cell proliferation. A prominent example is FOXM1, which enhances the 
expression of G1/S genes and is activated by CDK4/6–cyclin-dependent 
phosphorylation (18).  
CDK6 or CDK4	 overexpression has been demonstrated in several malignancies, 
including certain types of leukemia and lymphomas. In particular, CDK6, but not 
CDK4, has been proposed as a direct target of MLL fusion proteins and it has been 
found that MLL-rearranged ALL cells may gain a proliferative advantage from MLL 
fusion driven upregulation of CDK6 (19). 
1.4 TARGETING CYCLIN D1-CDK4/CDK6 COMPLEX 
Dysregulation of the cyclin D1-CDK4/CDK6 complex is frequently observed in cancer 
and contributes to aberrant cell proliferation and consequent tumourigenesis (20). 
These findings suggest that CDK4/CDK6 may be effective targets for therapeutic 
intervention. In particular, the fact that CDK6 is a direct target of MLL rearranged B-
cell acute lymphoblastic leukemia prompted us to investigate if pharmacological 
inhibition of CDK4/CDK6 could increase the efficiency of chemotherapeutic 
treatment and overcome drug resistance in this haematological malignancy.  
In the past, the first-generation CDK inhibitors, denominated pan-inhibitors, were 
nonselective CDK inhibitors that blocked CDK6 and CDK4 but also had significant off-
target effects (21).  
However, new selective ATP-competitive inhibitors of CDK4 and CDK6 that have the 
potential to cause dose-dependent decrease of retinoblastoma phosphorylation  and 
G1 arrest in cancers cells are currently in clinical trials: Palbociclib (PD0332991; 
Pfizer Inc., FDA-approved), Ribociclib (LEE011; Novartis), and Abemaciclib 
(LY2835219; Lilly, FDA Breakthrough Therapy status) (22) (Fig.2). 
A) 
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B) 
 
Fig. 2 Inhibiting CDK4/CDK6 in cancer. A) Chemical structure of selective CDK4/CDK6 
inhbitors (13) B) new selective ATP-competitive inhibitors of CDK4/CDK6: - Amebaciclib, - 
Palbociclib and – Ribocilcib (20). 
1.4.1 Ribociclib (LEE011) 
Ribociclib is an orally bioavailable small molecule that is a dual selective inhibitor of 
CDK4/CDK6 at nanomolar concentrations (23). The effectiveness of oral Ribociclib 
monotherapy is being investigated in subjects with breast cancer, glioblastoma, and 
liposarcoma (24). For example, Rader et al. reported that Ribociclib significantly 
reduced proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing 
cytostasis at nanomolar concentrations (25). Successful implementation of Ribociclib 
in the clinical settings will need to be done in combination with other agents because 
Ribociclib doesn’t induce cell death. Often, new targeted drugs have been 
introduced to patients with leukemia in combination with standard chemotherapy 
(26). The combination of Ribociclib with other drugs is under study. Ribociclib 
recently granted Food and Drug Administration priority review as first-line treatment 
of postmenopausal women with hormone-receptor positive, human epidermal growth 
factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in 
combination with letrozole (27). 
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1.5 Aim of the project 
Excessive cell proliferation induced by aberrant entry into the cell cycle is 
considered an hallmark of cancer. Recent findings have revealed that CDK4/6 and its 
regulatory subunit cyclin D1 are oncogenes and are overexpressed in a diverse set of 
human cancers, including B-cell acute lymphoblastic leukemia (B-ALL) (3). Moreover, 
CDK6 is essential for MLL-rearrenged leukemias (19). These findings suggest that 
CDK4/6 may be effective targets for therapeutic intervention. To test this possibility, 
we will inhibit CDK4 and CDK6 in four cell lines of B-cell acute lymphoblastic 
leukemia, characterized by different genetic rearrangements, using Ribociclib, an 
orally bioavailable, small molecule inhibitor of both CDK4 and CDK6. At low 
concentration, Ribociclib potently inhibit CDK4/6 without induction of apoptosis; 
therefore, standard treatment for newly diagnosed childhood B-ALL patients includes 
glucocorticoids (GC) treatment, but the molecular basis of GC sensitivity and 
resistance remains largely unknown; for this reason we will test if Ribociclib in 
combination with Dexamethasone, a glucocorticoid that is currently used as 
antitumour agent in the treatment of leukemia, may lead to synergistic killing of 
leukemia cells (28). 
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1.6 Abstract 
Background 
Dysregulation of the cyclin D1-CDK4/CDK6 complex contributes to aberrant cell 
proliferation and consequent tumourigenesis. Among the CDKs that control cell cycle 
progression, cyclin D-dependent kinases CDK4 and CDK6 are considered important 
oncogenic drivers in many cancers. CDK6 is a direct target of MLL rearranged B-cell 
acute lymphoblastic leukemia (B-ALL) and this prompted us to investigate if 
pharmacological inhibition of CDK4/CDK6 could increase the efficiency of 
chemotherapy and overcome drug resistance.  
Gene expression analysis performed in a cohort of childhood patients showed that 
CDK4 and CDK6 are highly expressed; therefore, Reverse Phase Protein Array (RPPA) 
analysis showed that cyclin D1 expression is higher in High Risk-MRD patients. These 
results suggest specific inhibition of cyclin D/CDK4/CDK6 axis as an attractive 
strategy to improve the effect of common chemotherapy on B-ALL patients.  
Standard treatment for newly diagnosed childhood B-ALL patients include 
chemotherapy treatment and although glucocorticoids (GC) are the most important 
drugs used in the treatment of acute lymphoblastic leukemia, the molecular basis of 
GC sensitivity and resistance remain largely unknown; understanding the molecular 
mechanisms related to GC cytotoxicity is crucial for modulating GC resistance. 
Materials and Methods 
To evaluate the effect of dual inhibition of CDK4/CDK6 in B-ALL, we used Ribociclib, 
an orally bioavailable highly specific CDK4/6 inhibitor. For this study we used four 
cell lines of B-cell acute lymphoblastic leukemia (B-ALL), characterized by different 
genetic rearrangements and different response to glucocorticoids; we treated them 
with Ribociclib alone and in combination with Dexamethasone (DEX), a glucocorticoid 
currently used in B-ALL treatment. MTT assay was performed to analyze the effects 
of treatment on cell proliferation; moreover, cell cycle analysis and annexin V/PI 
were carry on by flow citometry to assess cell cycle modification and cell viability. 
Western Blot analysis were performed to evaluate changing in signaling pathways 
induced by the treatment. 
Results 
Treatment with Ribociclib induced a strong cell cycle arrest in G1 phase in a time-
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dose dependent manner along with a dose-dependent decrease in phosphorylated 
retinoblastoma (Rb). We investigated whether treatment with Ribociclib could induce 
growth inhibition of B-ALL cell lines: we observed, in SEM and RCH-ACV, a strong 
growth inhibition at all drug concentration after continuous treatment; moreover, 
wash out of the inhibitor after 48h hours of treatment showed that both cell lines 
didn’t restore cell growth. These results show that Ribociclib could have an 
irreversible activity. A strong dose-dependent reduction of clonogenic potential was 
also observed in SEM cell line. Ribociclib exposure strongly synergize (CI<1) with DEX 
in SEM and RCH-ACV resistant cell lines with a strong decrease of proliferation and a 
significant increase of apoptotic cell death. Immunoblot analysis showed a decrease 
in phosphorylated Rb and Cyclin D1 starting from 48h of co-treatment and an 
increase in p27. Preliminary experiments showed a modest increase in glucocorticoid 
receptor (GR) after Ribociclib and combination treatment in SEM and RCH-ACV cells. 
To further confirm the synergistic effect, we evaluated mRNA level of GR targets and 
we found that GR, BTG1 and GILZ are overexpressed in combination treatment in SEM 
and RCH-ACV. The synergistic effect of Ribociclib-DEX combination was also 
confirmed on primary cultures derived from pediatric patients affected by B-acute 
lymphoblastic leukemia. Our findings support the concept that pharmacological 
inhibition of CDK4/CDK6 may represent a useful therapeutic strategy to control cell 
proliferation in B-ALL and provide new insight in understanding potential mechanism 
of glucocorticoid resistance. 
Keywords: CDK4/CDK6; cell cycle; B-acute lymphoblastic leukemia; 
chemotherapy; drug resistance; Ribociclib; glucocorticoid receptor 
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1.7 Materials and methods  
Cell culture  
The human leukemia cell lines RS 4;11, SEM, RCH-ACV and NALM6 were purchased 
from the American Type Culture Collection. Cells were cultured in RPMI 1640 (Life 
Technologies, Italy) supplemented with 10% fetal bovine serum (FBS), glutamine (2 
mM; Life Technologies, Italy), penicillin (100 U/ml; Life Technologies, Italy) and 
streptomycin (100 μg/ml; Life Technologies, Italy), and maintained at 37°C in a 
humidified atmosphere with 5% CO2.  
Primary leukemia cell cultures 
BCP-ALL patient samples were obtained after informed consent following the tenets 
of the Declaration of Helsinki. The study was approved by the ethical committee 
board of the University of Padova, the Padova Academic Hospital and the Italian 
Association of Pediatric Onco-Hematology (AIEOP). Diagnosis was made according to 
standard cytomorphology, cytochemistry and immunophenotypic criteria (31). All 
analyzed BCP-ALL samples were obtained at the time of diagnosis before treatment. 
Drug treatment  
Cells were grown to 60% confluence and then treated with Dexamethasone (Sigma-
Aldrich) and Ribociclib (Selleckchem), at a stock concentration of 10 mM and then 
used at different concentrations. Cells were treated for 72 h using scalar dilutions of 
Ribociclib (Sellekchem), combined with Dexamethasone (Sigma-Aldrich). Ribociclib 
was also added to drug solutions at fixed combination ratios. The effectiveness of 
various drug combinations was analyzed by the Calcusyn Version 2.1 software 
(Biosoft). The combination index (CI) was calculated according to the Chou-Talalay 
method (29-30). A combination index of 1 indicates an additive effect of the 2 drugs. 
Combination index values less than 1 indicate synergy, and combination index values 
more than 1 indicate antagonism.                                                                                                
MTT assay  
Proliferation was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay after treatment. Equal concentrations of cells were 
plated in triplicate in a 96-well plate and incubated with 10 μl MTT (Sigma-Aldrich, St 
Louis, MO, USA) for 4 h. Absorbance was measured at 560 nm using Victor3TM 1420 
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Multilabel Counter (PerkinElmer, Waltham, MA, USA). The growth inhibition50 
(GI50=compound concentration required to inhibit cell proliferation by 50%) was 
calculated by plotting the data as a logarithmic function of (x) when viability was 
50%. DMSO-treated cells viability was set to 100%. 
Measurement of cell growth inhibition 
Cell growth inhibition was determined by trypan blue exclusion assay plating SEM and 
RCH-ACV (2,5*105 cells/well) in 6 wells plate a day before treatment with Ribociclib 5 
μM and 10 μM. The following day, the starting cell number was calculated (T= 0h) 
and until the 3th day, every 24h cell number was calculated in continuous presence of 
the drug. 
To determine the persistence of the effects of drug exposure, SEM and RCH-ACV cells 
(2,5*105 cells/well) were plated in 6 well plate a day before treatment with 
Ribociclib 5 μM and 10 μM. After 48h of treatment, cells were collected and 
resuspended in complete fresh medium. Proliferation was measured using trypan 
blue exclusion assay and until the 3th day, every 24h cell number was calculated. 
Annexin V/Pi assay  
Surface exposure of phosphatidylserine on apoptotic cells was measured by flow 
cytometry with a Coulter Cytomics FC500 (Beckman Coulter) by adding Annexin V 
conjugated to fluorescein isothiocyanate (FITC) to cells according to the 
manufacturer's instructions (Annexin V Fluos, Roche Diagnostic). Simultaneously, the 
cells were stained with PI. Excitation was set at 488 nm, and the emission filters 
were at 525 and 585 nm, respectively, for FITC and PI.  
Flow cytometric analysis of cell cycle distribution  
Cell cycle distribution was measured by flow cytometry with a Coulter Cytomics 
FC500 (Beckman Coulter) by using propidium iodide in propidium iodide/RNase A 
staining.  
At 24h and 48h after drugs treatment, cells were harvested, washed with phosphate-
buffered saline solution (PBS) and fixed in 70% EtOH overnight at 4°C. After fixation, 
cells were washed twice with PBS before resuspension in 0.1% Triton X-
100/propidium iodide/RNase A solution (1mg/mL of PI and 4mg/mL RNase-A). Cells 
were incubated at room temperature in the dark light for 30 min and then processed 
for analysis. Samples were analyzed on a Cytomic FC500 flow cytometer (Beckman 
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Coulter). DNA histograms were analyzed using MultiCycle for Windows (Phoenix Flow 
Systems). 
Cell colony-formation assay  
Cells were harvested for 24h after drug treatment and were seeded in a fresh 12-well 
plate (1200 cells/well) and kept in culture undisturbed for 15 days, during which 
time the surviving cells spawned colonies of proliferating cells. Colony formation was 
analysed by staining the cells with diluted MTT.  
Immunoblotting  
Total protein extracts were isolated in lysis buffer prepared as follows: TPER Reagent 
(Pierce, Milano, Italy), NaCl 300 mM, orthovanadate 1 mM (Sigma, Milano, Italy), 
AEBSF 2 mM (PEFABLOC, Roche Biochemicals, Milano, Italy), Aprotinin 1 μg/ml 
(Sigma–Aldrich, Milano, Italy), Pepstatin-A 5 μg/ml (Sigma–Aldrich, Milano, Italy) and 
Leupeptin 1 μg/ml (Sigma–Aldrich, Milano, Italy). The protein concentration in the 
supernatant was determined using the BCA protein assay (Pierce, Milano, Italy). 
Equal amounts of protein (10 μg) were resolved using SDS-PAGE gels and transferred 
to Immobilon-P membrane (Millipore). Membranes were blocked with 3% BSA in 
tween 0.1% in PBS 1X (phosphate buffered saline) for at least 2 h under rotation at 
room temperature. Membranes were then incubated with primary antibodies 
overnight. Membranes were then incubated with peroxidase-conjugated secondary 
antibodies (Perkin Elmer, Italy) for 60 min. All membranes were visualized using ECL 
Select (GE Healthcare, Italy).  
Reverse-phase protein arrays (RPPA) 
Cell lysates were diluted to 1 mg/ml in Tris–Glycine SDS Sample Buffer (Invitrogen) 
containing 5% of -mercaptoethanol and boiled for 5 min immediately prior to array 
printing. Lysates were loaded into a 384-well plate and serially diluted with lysis 
buffer into four-point with the primary antibodies on anautomated slide stainer 
(Dako Autostainer Plus) using the CSA kit (Dako). Each antibody was previously 
subjected to extensive validation for single-band specificity by Western blot. Slides 
were air-dried and scanned on a Epson Perfection V300 Photo at 600 dpi. The TIF 
images of antibody- and Fast Green FCF stained slides were analyzed using 
Microvigene Software (VigeneTech Inc, Boston, MA, USA) to extract numeric intensity 
values from the array images dilution curves ranging from undiluted to 1:8. Protein 
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lysates were printed in duplicate in each array set onto nitrocellulose-coated slides 
(FAST slides) with the 2470 Arrayer (Aushon BioSystems). Printed slides were stored 
desiccated at -20°C until use. For RPPA analysis, one slide was stained with Fast 
Green FCF dye (Sigma) according to the manufacturer’s instruction, in order to 
estimate the total protein amount of each printed sample. Before antibody staining, 
the arrays were blocked for 3 h RT in blocking solution (2% I-Block in T-PBS). Arrays 
were then stained with the primary antibodies on anautomated slide stainer (Dako 
Autostainer Plus) using the CSA kit (Dako). Each antibody was previously subjected to 
extensive validation for single-band specificity by Western blot. Slides were air-dried 
and scanned on an Epson Perfection V300 Photo at 600 dpi. The TIF images of 
antibody- and Fast Green FCF stained slides were analyzed using Microvigene 
Software (VigeneTech Inc, Boston, MA, USA) to extract numeric intensity values from 
the array images. 
RNA interference with small interfering RNAs (siRNAs) 
To achieve a suitable gene silencing, SEM and RCH-ACV cells were transfected with 
300pmol of Cdk6 small interfering RNA (siRNA) purchased from Santa Cruz 
Biotechnology (sc-29264) as well as non targeting siRNA (siNEG, Thermofisher 
Scientific) confirmed to have minimal targeting of known genes using the Lonza’s 
Nucleofector™ Technology according to the manufacturer's instructions. All siRNA 
pools were resuspended to 20 μM in 1X siRNA buffer. 
RNA isolation and Reverse transcriptase polymerase chain reaction (RT-PCR)  
Total cellular RNA from cell lines and patient bone marrow was extracted with TRIzol 
reagent (Invitrogen). RNA quality was controlled using Nanodrop spectrophotometer. 
Subsequently, 1μg of total RNA was reversely transcribed using random hexamers and 
Superscript II (Invitrogen), according to the manufacturer’s instructions. 
Real time PCR  
Real-time quantitative (RQ-PCR) was performed on an Applied Biosystems 7900 HT 
Sequence Detection System using SYBR Green PCR Master Mixture Reagents (Applied 
Biosystems; Forest City, CA). Experiments were performed minimum as triplicate and 
used for relative quantity study. Primers used for RQ-PCR analysis were for GR gene 
(glucocorticoid receptor), BTG1, GILZ and CDK6. All expression values were 
normalized using expression of GUS as an endogenous control (Table 1). 
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Table 1. Primer sequences used for RQ-PCR analysis of B-ALL cells treated with 
combination treatment 
 Forward Reverse 
GR 5’-CCTTCTGCGTTCACAAGCTA-3’ 5’-TTCTTTGGAGTCCATCAGTG-3’ 
BTG1 5’-TGTTCAGGCTTCTCCCAAGT-3’ 5’-CTACCATTTGCACGTTGGTG-3’ 
GILZ 5’-GAAGGAGCAGATCCGAGAGC-3’ 5’-GGCTCAGACAGGACTGGAAC-3’ 
CDK6 5’-ACTTCGGCCTTGCCCGCATC-3’ 5’-GGGGGTGGCGTAGCTGGACT-3’ 
GUS 5’-GAAAATATGTGGTTGGAGAGC-3’ 5’-CGAGTGAAGATCCCCTTTTTA-3’ 
Statistical analysis 
All experiments were performed with a minimum of three technical and three 
biological replicates, and values reported are the mean of the three biological 
replicates, unless otherwise indicated. Error bars represent the standard deviation 
(SD) from the mean, unless otherwise indicated. When comparing data from 
experiments with multiple groups, a multicomparison ANOVA was used with the 
Newman-Keuls. For all tests, differences were considered statistically significant at a 
P value of 0.05 or less. All statistical analyses were performed using the GraphPad 
Prism software. 
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1.8 Results 
Cyclin D1-CDK4/6 complex is dysregulated in B lymphoblastic leukaemic patients 
To investigate if Cyclin D1-CDK4/6 complex plays a role in childhood B-cell acute 
lymphoblastic leukemia (B-ALL) we performed some analysis to understand the status 
of this complex in a cohort of pediatric patients. We evaluated gene expression of 
CDK4 and CDK6 and we observed a significantly overexpression of CDK4 in MLL-
rearrenged leukemia respect to normal bone marrow and a significantly 
overexpression of CDK6 in all leukemia subtypes respect to normal bone marrow 
confirming that these kinases are dysregulated in B-ALL (Fig.3). 
 
Fig. 3 CDK4/CDK6 are overexpressed in B-ALL patients compared to normal bone marrow. 
CDK4/CDK6 gene expression level was analyzed in 299 patients and compared to bone marrow 
of healthy donors. 
For what concern Cyclin D1, Reverse phase protein microarray (RPPA) analysis, in a 
cohort of pediatric patients, showed that there are high levels of Cyclin D1, in high 
risk patients. Among childhood ALL patients, white blood cells counts (WBC) and 
minimal residue disease (SR, standard risk; HR, high risk) represent independent 
predictors of an adverse outcome. We determined whether high levels of Cyclin D1 
expression were associated with increased WBC at diagnosis. To do this, we 
compared infant ALL patients with “low” (<50,000) and “high” (>50,000) WBC counts, 
and found that patients expressing high WBC presented higher Cyclin D1 levels at 
diagnosis. We also determined whether high levels of Cyclin D1 expression were 
correlated with minimal residue disease at diagnosis; we observed that there were 
higher levels of Cyclin D1 expression in high risk patients respect to standard risk 
patients. We found higher Cyclin D1 expression in relapsed patients respect to not 
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relapsed (Fig.4). Taken together, this data demonstrate that Cyclin D1/CDK4/CDK6 
complex is generally deregulated in childhood B-cell acute lymphoblastic leukemia. 
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Fig. 4 High levels of Cyclin D1 in B-ALL patients that relapse and in high risk. 
(A-C) RPPA analysis in a cohort of childhood B-ALL has revealed high levels of Cyclin D1 in 
relapsed and high risk patients. (D) CIR analysis showed that those patients with high levels of 
Cyclin D1 relapse before than those patients with low levels of Cyclin D1. 
Knockdown of Cdk6 decreases cell proliferation in B-ALL cell lines and induces a 
G1 cell cycle arrest 
Since our preliminary observation indicate that CDK4/CDK6 signaling is 
hyperactivated in B-ALL patients, in order to assess the effective role of CDK4/CDK6-
cyclin D1 signal in B-ALL in maintaining hyperphosphorylated RB and in supporting 
cell proliferation, we evaluate the effect of CDK4/CDK6 gene silencing on B-ALL cell 
line RCH-ACV. Cells were transiently transfected with a CDK6 and CDK4 siRNA pool 
and cell proliferation was measured after 48 h by MTT assay. Silencing of CDK4/CDK6 
was confirmed by western blot analysis (Fig.5 A,B). The best characterized direct 
phosphorylation targets of cyclin D-dependent kinase are RB proteins (pRB), SMAD2, 
SMAD3 and FOXM1 transcription factor. As expected, CDK4/CDK6 silencing induced 
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strong dephosphorylation of pRB (S780), FOXM1 (T600) and SMAD2/3 (T8), followed 
by the activation of the cell cycle inhibitor p21 (Fig 5A,B). Moreover, a decrease of 
pRB total protein was also observed, as previously demonstrated by Rader et al. (25). 
Considering that the phosphorylation of RB, FOXM1 and SMAD2/3 are essential to the 
activation of the cell transcriptional activity that promotes G1-S transition, we 
evaluate CDK4/CDK6 depletion effects on cell proliferation. Flow cytometric analysis 
has revealed a significant retention of cell in G1-phase of the cell cycle (Fig.5C) 
along with a remarkable decrease of cell proliferation (Fig.5D).  
Fig. 5 Ckd4 and Cdk6 knockdown in RCH-ACV cells induces a significant decrease in cell 
proliferation and a G1 phase arrest. RCH-ACV were transfected with a specific CDK/CDK6 
siRNA and a negative siRNA as a control. (A) Western blot analysis confirmed the knockdown 
of endogenous both CDK4 and CDK6 and the reduced expression of pRB, pRB (s780), SMAD2/3 
(T8) and FOXM1 (T600). (B) Densitometric analysis of immunoblots. (C) Cell cycle analysis of 
RCH-ACV cells after 48 h from the transfection. (D) Cell viability analysis, was performed by 
MTT assay, after 72 h after transfection. All the data are presented as mean ± SEM of three 
independent experiments. *, p <0.05: ** p < 0.01, ***p<0.001. 
To further analyze the role of CDK6 on cell cycle progression in B-ALL, we analyzed 
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the cell-cycle phase distribution in SEM and RCH-ACV cells following Cdk6 
knockdown. As shown in Fig.6 in both cell lines, there was an increase of the 
percentage of cells in G1 and a corresponding decrease of cells in S phase compared 
with non-specific (NSC) control cells. 
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Fig. 6 Cdk6 downregulation in SEM and RCH-ACV cells by a specific Cdk6 siRNA pool 
induces a G1 cell cycle arrest. In SEM (A) and RCH-ACV cell (B) lines the endogenous Cdk6 
expression was blocked by knockdown performed by using Cdk6 transient silencing. After 48h 
of knockdown, cell cycle analysis was performed to investigate the effect of Cdk6 inhibition 
in cell cycle-phase progression. Results are the average ± SD of three independent 
experiments in triplicate. 
Ribociclib induces cell growth inhibition in B-ALL cell lines 
To explore the effect of Ribociclib on cell proliferation in B-ALL, we choose 4 B-ALL 
cell lines including RS4;11, NALM6, SEM and RCH-ACV. Cells were exposed to the 
inhibitor for 72 h at concentrations ranging from 0.001 to 100 μM. The GI50 evaluated 
by MTT assay after 72 h was in the micromolar range for all cell lines treated (Fig.7). 
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Fig. 7 Ribociclib has a modest effect on cell viability. Cells were treated at the indicated 
concentration and cell viability was assessed by MTT test after 72 h of incubation. GI50 is in 
the micromolar range for all cell lines treated. Data are expressed as mean ± SEM of three 
independent experiments. 
Since we have found that Ribociclib induces growth inhibition in B-ALL cell lines; in 
this context, we treated both SEM and RCH-ACV cell lines with Ribociclib 5 μM and 10 
μM for 24, 48, and 72 h. Cell growth inhibition was evaluated by Trypan Blue 
exclusion and we observed, in both cell lines, a strong growth inhibition at all drug 
concentrations. Removal of the inhibitor after 48 h hours from the medium showed 
that both cell lines didn’t restore cell growth (Fig.8a-b) 
Fig. 8a Ribociclib induces growth inhibition in B-ALL cell lines after continuous treatment 
of the inhibitor. 
 
Fig. 8b Ribociclib induces growth inhibition in B-ALL cell lines after wash out of the 
inhibitor. 
To determine whether Ribociclib affected the colony formation ability of B-ALL cell 
lines, we performed colony formation assay in SEM cell line. After a treatment of 24h 
with Ribociclib at the concentration of 5 μM and 10 μM, we washed out cells and we 
performed colony formation assay in methocult for 15 days. Colony numbers were 
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then quantified in each group. Consistently, we found that Ribociclib dramatically 
reduced the ability to form colonies in treated SEM cell lines, compared to the 
control group in a dose-dependent manner (Fig.8c).  
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Fig. 8c Ribociclib affected the colony formation ability of B-ALL cell lines:  A) Clonogenic 
assay in SEM cells treated with 5 μM and 10 μM of Ribocliclib, washed out after 24 h of 
treatment and recovery for 15 days; B) colony counting to assess growth of cells treated with 
Ribociclib that statistically reduced the ability to form colonies in treated SEM cell lines, 
compared to the control group in a dose-dependent manner. Data are expressed as mean ± 
SEM of three independent experiments. Statistical analysis was performed using ANOVA 
multicomparison test against the cells treated with the non-treated control; * p ≤ 0.05. 
Ribociclib induces G1 arrest but not apoptosis in B-ALL cell lines 
Cell cycle analysis was undertaken on SEM and RS4;11 treated with Ribociclib at 5 
and 10 µM for 24 and 48 h. As shown in Fig.9a Ribociclib induces a significant 
increase in G1 phase along with a decrease in S phase in both cell lines. 
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Fig. 9a CDK4/CDK6 inhibition in SEM and RS4;11 cells by Ribociclib treatment induces a G1 
cell cycle arrest. (A) SEM and (B) RS4;11 cell lines were treated with the indicated 
concentration of Ribociclib. After 24 and 48 h of treatment, cell cycle analysis was performed 
to investigate the effect of CDK4/CDK6 inhibition in cell cycle-phase progression. Results are 
the average ± SD of three independent experiments in triplicate. 
Moreover, flow cytometric analysis carried out after different times of treatment 
indicate that Ribociclib doesn’t induce apoptosis as demonstrated by non significant 
appearance of annexin-V positive cells in both cell lines when treated with Ribociclib 
even at the concentration of 10 µM for 24 and 48 h (Fig.9b). 
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Fig. 9b CDK4/CDK6 inhibition in SEM and RS4;11 cells by Ribociclib treatment doesn’t 
induce apoptosis. A) SEM and B) RS4;11 cells were treated with Ribocliclib at the 
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concentration of 5 μM and 10 μM, for 24 and 48 h. Induction of apoptosis was assessed by flow 
cytometry after staining of the cells with Annexin-V-FITC and propidium iodide (PI). Dual 
staining permits discrimination between live cells (annexin-V-/PI-), early apoptotic cells 
(annexin-V+/PI-), late apoptotic cells (annexin-V+/PI+) and necrotic cells (annexin-V-/PI+). 
Shown are the mean ± standard error of mean (SEM) of 3 separate experiments. 
To confirm that the growth inhibition observed in B-ALL cell lines was due to a 
targeted impairment of CDK4/6 signaling, we analyzed the levels of phosphorylated 
retinoblastoma following treatment with Ribocliclib. The mechanism by which 
CDK4/CDK6 promote cell proliferation and G1-S cell cycle transition depend on the 
phosphorylation of critical substrate proteins. As depicted in Fig 4B-C in all studied B-
ALL cell lines, treatment with ribociclib induced a rapid and dramatic decrease of 
pRB phosphorylation at S780 already at the lowest concentration of inhibitor, 
together with a dephosphorylation of  FOXM1 (T600) (delayed in RS 4;11) and at later 
time of SMAD3 (T8).  By these dephosphorylation, the signaling that drive the 
transition through G1-S phase is arrested (Fig.10) 
A) 
 
B)  
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Fig. 10 Effect of CDK4/CDK6 inhibition on the expression of proteins involved in G1 phase 
of cell cycle. Ribociclib treatment decreases protein levels of pRB, pRB (s780) SMAD2/3 (T8) 
and FOXM1 (T600) in A) SEM and B) RS4;11 cell lines after 24 and 48 h; cells were collected, 
and protein extracts were subjected to western blot analysis for the indicated antibodies. 
Actin was used as loading control. The right part of the table shows densitometric analysis of 
immunoblot. All the data are presented as mean ± SEM of three independent experiments. *, 
p <0.05: ** p < 0.01, ***p<0.001. 
Ribociclib synergizes with dexamethasone in inhibiting B-ALL proliferation  
Since CDK4/CDK6 pharmacological inhibition induces a strong G1 phase arrest in B-
ALL cell lines, we investigated if this effect could enhance killing of B-ALL cells. in 
combination with the most commonly used chemotherapeutics in B-ALL treatment. 
Four different B-ALL cell lines, two glucocorticoid-resistant (RCH-ACV, SEM) and two 
glucocorticoid-sensitive (NALM-6, RS4;11) were treated for 72 h with Ribociclib in 
combination with chemotherapeutic agents (i.e. Dexamethasone, asparaginase, 
daunorubicin and vincristine) used normally to treat pediatric B-ALL patients. More 
specifically, Ribociclib was combined with different drugs at fixed molar combination 
ratio, and cell viability analyzed by MTT assay The obtained results indicate that 
among the different drugs, only Dexamethasone in association with Ribociclib induces 
synergism (Fig.11A). These results are in well agreement with that reported recently 
by (30) in T-cell acute lymphoblastic leukemia. Another thing that is to note is that 
we observed synergism also in Dexamethasone resistant cell lines.  
In light of the strong synergy with Ribociclib in combination with glucocorticoids we 
focused our further study on this combination.  
As demonstrated by the values of combination index (CI) according to Chou and 
Talalay (28,29) (Fig.11B) in all cell lines tested, Ribociclib has a synergistic effect 
with Dexamethasone (CI<1). Glucocorticoids (GC) are the most important drugs used 
in the treatment of acute lymphoblastic leukemia, but the molecular basis of GC 
resistance remains largely unknown and understanding the molecular mechanisms 
related to GC cytotoxicity is crucial for modulating GC resistance. 
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Fig. 11 Ribociclib strongly synergizes with Dexamethasone in B-ALL cell lines. A) Cells 
were treated at the indicated concentration and at fixed combination ratio 1:1 in SEM, RCH-
ACV and NALM6 (0.0001-10 μM for both drugs) and 1:1000 in RS4;11 (0.0001-10 μM for 
Ribociclib and 0.0001-10 nM for Dexamethasone); cell viability was assessed by MTT test after 
72 h of incubation. Data are expressed as mean ± SEM of three independent experiments. B) 
Combination index values (CI) in B-ALL cell lines treated with Ribociclib in combination with 
Dexamethasone. 
The synergistic effect of Ribociclib-Dexamethasone combination was also confirmed 
on primary cultures derived from pediatric patients affected by B-acute 
lymphoblastic leukemia (Fig.12). 
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Fig. 12 Synergistic effect of Ribociclib-Dexamethasone combination in B-ALL primary 
cultures. A) Cells were treated at the indicated concentration and at fixed combination ratio 
1:1 (0.001-100 μM for both drugs); viability was assessed by MTT test after 48 hours of 
incubation; B) combination index values (CI) at ED50 in B-ALL primary cultures treated with 
Ribociclib in combination with Dexamethasone. 
Combination of Ribociclib and Dexamethasone induces G1 arrest and apoptosis 
in B-ALL cell lines  
To explore the potential role of Ribociclib and Dexamethasone combination in 
Dexamethasone resistant B-ALL, we next studied the effects of this combination on 
cell cycle and cell viability of Dexamethasone resistant cell lines, SEM and RCH-ACV.  
The cell cycle analysis showed that there was a significant shift in cell cycle 
distribution of both cell lines in response to combination treatment after 24 and 48 
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h; in particular, we observed a considerable increase in G1 phase arrest and a 
consequent decrease in S phase, in combination treatment respect to control and 
single treatment group (Fig.13A-B).  
As demonstrated by western blot, this arrest of cell cycle upon combined treatment, 
could be mediated by a reinforced dephosphorylation of CDK4/CDK6 target. In 
particular, combined treatment induce a significant decrease of pRB (S780), SMAD2/3 
(T8), FOXM1(T600) along with a strong increase of CDK4/CDK6 inhibitor p16 (Fig.13C-
D). 
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Fig. 13 CDK4/CDK6 inhibition in SEM and RCH-ACV cells by combination treatment induces 
a stronger G1 cell cycle arrest respect to single treatment.  (A) SEM and B) RCH-ACV cell 
lines were treated with the indicated concentration of Ribociclib, Dexamethasone and 
combination between Ribociclib and Dexamethasone. After 48 h of treatment, cell cycle 
analysis was performed to investigate the effect of the drug combination in cell cycle-phase 
progression. Results are the average ± SD of three independent experiments. Combination 
* * 
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treatment enhances the decrease of cell cycle protein expression of S780 phosphorylated 
retinoblastoma, retinoblastoma, SMAD2/3 (T8) and FOXM1 (T600) in SEM (C) and RCH-ACV (D) 
cell lines; after 48 h cells were collected, and protein extracts were subjected to western 
blot analysis for the indicated antibodies. 
Next, we asked whether the synergistic effects of Ribociclib plus Dexamethasone 
reflect enhanced apoptotic responses to glucocorticoids therapy. Annexin V–
propidium iodide (PI) staining indicated increased apoptosis in SEM and RCH-ACV cell 
treated with Ribociclib 1 and Dexamethasone 1 for 72 h (Fig.14). 
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Fig. 14 Combination treatment of Ribociclib and Dexamethasone induces strong apoptosis 
in SEM and RCH-ACV. Annexin V staining of cells following 72 h treatment with Ribociclib at 
1 µM and Dexamethasone 1 µM compared with controls. A) SEM, B) RCH-ACV.  The % of 
apoptotic cells is referred to the sum of early (A+/PI-) and late (A+/PI+) apoptotic cells. Data 
are expressed as mean ± SEM of three independent experiments. Statistical analysis was 
performed using ANOVA multicomparison test against the cells treated with the non-treated 
control; * p ≤ 0.05; p≤ 0.001. 
Combination of Ribociclib and Dexamethasone induces an increase in 
Glucocorticoid receptor expression in B-ALL cell lines 
To further test the efficacy of combination treatment and to assess the therapeutic 
role of CDK4/CDK6 inhibition in the treatment of glucocorticoid-resistant leukemias, 
we treated SEM and RCH-ACV with combination of Ribociclib and Dexamethasone. We 
analyzed the effects of this combination at protein level after 48 h and at 
transcriptional level after 24 h to explore the mechanisms mediating the reversal of 
glucocorticoid resistance upon CDK4/CDK6 inhibition. We found a modest increase in 
glucocorticoid receptor expression in SEM and RCH-ACV treated with Ribociclib or 
Dexamethasone for 48 h. In contrast, Ribociclib plus Dexamethasone treatment 
resulted in a higher upregulation of glucocorticoid receptor protein levels (Fig.16A-
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C). At the transcriptional level, quantitative real time PCR showed a synergistic and 
significative upregulation of glucocorticoid-regulated genes such as GILZ and BTG1 in 
SEM and RCH-ACV treated with combination of Ribocilib and Dxamethasone for 24 h. 
There is also a moderate increase in glucocorticoid receptor in SEM cell line and a 
significative increase in glucocorticoid receptor expression in RCH-ACV cell line 
(Fig.16B-D). These results suggest that pharmacological inhibition of CDK4/CDK6 
enhances glucocorticoid receptor autoregulation and glucocorticoid expression, 
suggesting an increased in glucocorticoid resistant B-ALL cells. 
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Fig. 16 Ribociclib plus dexamethasone enhances glucocorticoid receptor autoregulation 
and glucocorticoid sensitivity in glucocorticoid resistant B-ALL cells. In panel A) SEM and C) 
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RCH-ACV cells were treated with Ribociclib (1 μM), dexamethasone (1 μM) and combination 
treatment for 48 h. Cells were collected after treatment and were subjected to western blot 
analysis for Glucocorticoid receptor (GR) and housekeeping expression. In panel B) SEM and D) 
RCH-ACV were treated for 24 h with Ribociclib (1 μM), dexamethasone (1 μM) and 
combination treatment; Glucocorticoid receptor, BTG1 and GILZ mRNA levels were analyzed 
by RQ-PCR analysis and results were normalized to GUS mRNA levels. Data are expressed as 
mean ± SEM of three independent experiments. Statistical analysis was performed using 
ANOVA multicomparison test against the cells treated with the non-treated control; * p ≤ 
0.05; p≤ 0.001. 
CDK4/CDK6 silencing induce GR expression and sensitize B-ALL cells to 
dexamethasone  
In order to assess potential off-target effects induced by ribociclib treatment on GR, 
we evaluate its protein expression after CDK4/CDK6 gene silencing (Fig.2A, 17A-B). 
As expected, similarly to ribociclib treatment, CDK4/CDK4 silencing strongly 
enhanced GR expression (Fig.17A-B). Moreover, accordingly to pharmacological 
inhibition, gene silencing significantly sensitize RCH-ACV cells to dexamethasone 
treatment (Fig.17C).  
 
Fig. 17 Effects of specific CDK4/CDK6 silencing in RCH-ACV cells. Panel A. Knowdown of 
CDK4/CDK6 induce a significant increase of glucocorticoid receptor (GR) expression (Panel B) 
and sensitize cells to the action of dexamethasone. Panel C. Silenced cells were treated with 
dexamethasone (1M and 10 M) for 48 h and viability was assessed by MTT assay. Data are 
presented as mean ± SEM of three independent experiments. ** p < 0.01, ***p<0.001. 
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1.9 Discussion 
Excessive cell proliferation induced by aberrant entry into the cell cycle is 
considered an hallmark of cancer. Recent findings have suggested that CDK4/6 and 
its regulatory subunit cyclin D1 may be potential oncogenes and are overexpressed in 
a diverse set of human cancers. Moreover, CDK6 is essential for MLL-rearrenged 
leukemias (20).  Success in targeting the cell cycle in cancer with broad spectrum 
CDK inhibitors has been modest, mainly because lack of selectivity and high toxicity. 
The CDK4/CDK6 specific inhibitor Ribociclib, received FDA approval as first-line 
treatment for HR+/HER2- metastatic breast cancer in combination with any 
aromatase inhibitor (33). 
Our study, for the first time, tests a CDK4/CDK6 specific inhibitor in the treatment of 
B-ALL, demonstrating significant efficacy in vitro as a single agent and in 
combination with Dexamethasone. 
Gene expression analysis performed on 299 B-ALL patient samples showed that CDK4 
and CDK6, are highly overexpressed in comparison to bone marrow derived from 
healthy donors. These preliminary results prompted us to investigate if inhibiting 
CDK4 and CDK6 in B-ALL could be a good strategy to sensitize resistant leukemia 
subtypes to chemotherapy. 
This study was performed on 4 B-ALL cell lines, characterized by different 
chromosomal rearrengements; due to the observation that CDK4/CDK6 signaling is 
higly active in B-ALL, thus maintaining hyperphosphorylated retinoblastoma and 
supporting cell cycle progression through the G1/S checkpoint, we chose to 
interrogate the effect of CDK4/CDK6 depletion on B-ALL cell lines. We knocked-down 
CDK4/CDK6 genes ina B-ALL cell line and analyzed both cell viability and 
proliferation. We observed a significant reduction in cell proliferation along with a 
strong arrest in G1 phase of the cell cycle.  
We next investigated whether pharmacological inhibition phenocopied siRNA-
mediated protein depletion: we found that at low concentration, Ribociclib induced 
a strong G1 cell cycle arrest. As expected a strong reduction of pRB (S780) but a 
reduction in total protein was also observed in well agreement with CDK4/CDK6 
silencing. Analougsly Ribociclib treatment induces a significative dephosphorylation 
of both FOXM1 (T600) and SMAD2/3 (T8), two important targets of CDK4/CDK6.  
The FOXM1 transcription factor has been identified as potential target of CDK4/6 
signaling and also as recently reported by our group and others, it is involved in B-
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ALL proliferation (34-35). The treatment with ribociclib induced a decrease in the 
expression of phosphorylated form of FOXM1, suggesting its deactivation and a 
consequent decrease of its transcriptional activity. SMAD2/3 are the principal 
mediator for TGF-b antiproliferative responses and regulate the transcription of 
important cell cycle mediators such as c-myc, p21 and p15. SMAD2/3 are direct 
target of inhibitory phosphorylation by CDK4/CDK6 during cell cycle (36-37). 
Together with FOXM1, the decrease in T8 phosphorylation site of SMAD2/3 upon 
Ribociclib treatment, and thus its activation, further reinforced the antiproliferative 
effect of the studied drug. 
We demonstrated that Ribociclib treatment causes a decrease in cell proliferation 
and cell colony formation; therefore, for the first time, we showed that Ribociclib 
acts irreversibly on cell proliferation of B-ALL cell lines after 48h of treatment and 
successive wash out, maybe due to the prolonged G1 arrest that negatively regulates 
the phosphorilation of CDK4/CDK6 downstream targets, importants for cell cycle 
progression. 
From the point of view of the cytotoxic mechanism of action of Ribociclib, we 
provided evidence that the compound has a cytostatic effect and it doesn’t induce 
apoptosis; as demonstrated by Chen-Kiang for Palbocilib (38), another CDK4/CDK6 
inhibitor, it is possible that treatment of B-ALL with Ribociclib may halt gene 
expression in G1 and prevent the expression of genes programmed for other phases, 
thereby sensitizing tumour cells for cytotoxic killing. Numerous mechanisms have 
been proposed to explain the lack of effective glucocorticoid-induced apoptosis in 
prednisone poor responders; however molecular basis of glucocorticoids resistance in 
acute lymphoblastic leukemia remain unclear (39). To this regard we examined if 
combining Ribociclib with the chemotherapeutics used in B-ALL therapy could 
increase their efficacy. Our results clearly indicate a strong synergistic effect (CI<1) 
between Ribociclib and Dexamethasone in the four B-ALL cell lines tested. In 
particular, it is important to note that Ribociclib is able to partially reverse the 
glucocorticoid resistance in SEM and RCH-ACV, that are normally resistant to 
dexamethasone. Furthermore, these results were confirmed, in a more specific way, 
in the same cell lines after combination treatment of Ribociclib and Dexamethasone; 
we found an increase in the Glucocorticoid receptor at protein and mRNA level, we 
observed also a synergistic upregulation of glucocorticoid-regulated genes such as 
BTG1, GILZ.  
Numerous studies on the mechanisms of glucocorticoids resistance have established 
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that an effective upregulation of Glucocorticoid receptor gene in response to 
glucocorticoids is required for the activation of apoptosis in human leukemias (40). 
Our results showed that combination treatment in SEM and RCH-ACV causes a 
significative increase of apoptotic cells after 72 h. 
Another important finding is that the increase of GR expression is increased also 
when CDK4/6 are knockdown by specific siRNA indicating that the effect of Ribociclib 
are not due to an off-target. Importantly this occur in glucorticoid resistant cells thus 
these results could be important in the light of the fact that one of the negative 
prognostic factors in the cure of B-ALL is the resistance to glucocorticoids. 
Our findings indicate that Ribociclib acts synergistically with Dexamethasone and 
thus might overcome potential resistance to treatment; moreover, a combinatorial 
strategy might also enable lower doses of glucocorticoids to be used, minimizing 
toxicities while maintaining therapeutic efficacy. We can conclude that targeting 
CDK4/CDK6 kinase activity may improve the treatment of glucocorticoid-resistant B-
ALL. 
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2.1 General introduction 
The failure of treatment of cancer patients often occurs as a result of intrinsic or 
acquired drug resistance of the tumour to chemotherapeutic agents. The resistance 
of tumours occurs not only to a single cytotoxic drug, but also occurs as a cross-
resistance to a whole range of drugs with different structures and cellular targets 
(1). This phenomenon is called multiple drug resistance (MDR) and it is defined as a 
phenotype of the cells resistant to multiple structurally and functionally different 
drugs. Such resistance is multifactorial and may be due to various mechanisms (2). 
The most common mechanism of MDR is due to the overexpression of membrane 
efflux pumps called ATP-binding cassette (ABC) transporters, which can result in an 
increased efflux of the cytotoxic drugs from the cancer cells, thus lowering their 
intracellular concentrations; MDR severely limits the efficacy of cancer 
chemotherapy in a variety of common malignancies (1).  
Cellular mechanisms of drug resistance have been intensively studied and 
experimental models can be easily generated by in vitro selection with cytotoxic 
agents, such as paclitaxel, doxorubicin, or vinblastine (3). Among several mechanisms 
underlying the development of MDR, the process of P-gp mediated drug efflux plays a 
key role (Fig.1). This has prompted extensive investigations towards the 
development of new candidate structures as P-gp inhibitors (4). 
 
Fig. 1 Mechanisms behind multidrug resistance: The most common mechanism of MDR is 
due to the overexpression of ABC transporters, which can result in an increased efflux of the 
cytotoxic drugs from the cancer cells (6). 
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It is known that solid tumours are enriched of cancer stem cells that are a small 
subpopulation of stem-like cells and have the capability for tumour-initiation and 
self-renewal. This population of cells is associated with greater resistance to 
conventional therapy (5). We focused on medulloblastoma because it is one of the 
most frequent childhood brain tumours and there is the need of developing new 
treatment to reduce long-term toxicity of therapy. 
To this regard we will investigate if overcoming/inhibiting ABC drug transporters 
could enhance the efficacy of current chemotherapy regimens. 
2.1.1 ATP binding cassette transporters 
ABC transporters are a group of plasma membrane glycoproteins consisting of both 
transmembrane domains and distinctive nucleotide-binding domains, which generate 
energy from ATP hydrolysis to actively transport a variety of compounds across (7). 
Currently, 49 members of the ABC transporter family have been isolated and 
identified (8); three members of the ABC transporter family, ABCB1 (P-glycoprotein), 
ABCC1 and ABCG2, appear to play an important role in the development of multidrug 
resistance in cancer cells (Fig.2) (7). All three have broad, overlapping substrate 
specificity and promote the elimination of various cancer chemotherapeutics such as 
taxanes, topoisomerase inhibitors and antimetabolites (9). 
 
Fig. 2 The structure of three member of ABC family that play an important role in 
multidrug resistance. a) ABCB1 b) ABCC1 c) ABCG2 (4).  
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2.1.2 Targeting side population in Medulloblastoma 
Medulloblastoma (MB) is a highly invasive tumour arising from embryonal cells in the 
cerebellum and is the most-common type of paediatric brain tumour, accounting for 
about 20% of all childhood brain cancers. Standard protocol therapy consists of 
surgical resection, craniospinal irradiation, and chemotherapy with a treatment 
success rate of approximately 70–75% among children aged ≥3 years (10). 
The World Health Organization classifies medulloblastoma into subtypes based on 
histological traits, but disease prognosis is better predicted by four different non-
histological subgroups, based on the global genome sequencing profile: 1) WNT; 2) 
Sonic hedgehog (SHH); 3) Group 3 (N-MYC amplification); and 4) Group 4 
(heterogenous genes) (Fig.3) (11). 
Despite of the efficacy of this protocol in increasing the survival rate, in particular 
for high-risk patients, there is the need of developing new treatment to reduce long-
term toxicity of therapy such as very severe neurologic and neuroendocrine 
consequences. 
 
Fig. 3 Medulloblastoma subgroups (12). 
The discovery of cancer stem cells in solid tumours has changed the view of 
carcinogenesis and chemotherapy. One particularly intriguing property of stem cells 
is that they express high levels of specific ABC drug transporters (13). 
Within cancer stem cells there is cell population identified as “side population” (SP), 
based on ABC transporters-mediated efflux of Hoechst 33342 dye (14); moreover, 
these cells are pluripotent, have greater growth capacity and resistance to cytotoxic 
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drugs as compared to non-SP cells (15).  
SP cells have been successfully identified in a wide range of solid tumours, including 
breast cancer, lung cancer, prostate cancer, ovarian cancer, pancreatic cancer, 
glioblastoma and medulloblastoma. This population plays a critical role in tumour 
initiation, maintenance, progression, and relapse (16). 
We focused on MB side population because drug uptake into the brain depends on 
various factors, including the physical barriers presented by the blood–brain barrier 
(BBB) and it has been found that ABC transporters are presents at the BBB. These 
transporters can remove a drug from the central nervous system or prevent its entry 
in the BBB, thereby limiting the accumulation of such drugs in the brain (17). 
Side population not only have the characteristics of tumour stem cells, it is also more 
resistant to the effects of drugs, and may contribute to the overall drug resistance 
phenotype of relapsed or resistant cancers; for these reasons, it is essential the 
devolopment of new drugs to eradicate SP cells. Therefore, targeting the SP cells is 
an attractive strategy for overcoming drug resistance in solid tumours. 
2.1.3 New synthetic ecdysteroids as innovative therapeutic strategy for MDR 
Ecdysteroids are hydroxysteroids with a characteristic 7-en-6- one moiety in their B-
ring and these compounds are analogues of the molting hormones of arthropods (18). 
Quite recent studies from Hunyadi et al. found that certain ecdysteroid derivatives, 
such as the most common 20-hydroxyecdysone (Fig.4), significantly decrease the 
resistance of MDR murine leukemia cell line expressing the human ABCB1 transporter 
or P-glycoprotein to doxorubicin, a known chemotherapeutic agent that is a substrate 
of the ABCB1 transporter (19). 
 
Fig. 4 Structure of 20-hydroxyecdysone. 
Multicomponent reactions (MCRs) are convergent chemical processes in which more 
than two starting materials react to form a product, incorporating essentially most of 
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the atoms of the reagents. One of the most versatile MCRs is the Ugi four-component 
reaction (U-4CR), which is based on the exceptional reactivity of the isocyanide 
functional group and widely applied in diversity-oriented synthetic strategies. Here 
we exploit the reactivity of the 6-keto-7-ene group of 20-OH-ecdysone, 
demonstrating it as a precursor of an amine or isocyanide functionality. Starting from 
6-amino- and 6-isocyanide-containing ecdysone derivatives, we were able to prepare 
a small family of ecdysteroid-peptide conjugates.  
The newly synthesized derivatives were evaluated in a panel of ABCB1-
overexpressing drug-selected human cancer cell lines and in medulloblastoma cell 
lines, for their antiproliferative activity and anti-P-gp activity. 
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NOVEL ECDYSTEROIDS RESENSITIZE MULTIDRUG RESISTANCE 
CANCER CELLS TO CHEMOTHERAPEUTIC AGENTS THROUGH 
MODULATION OF P-GLYCOPROTEIN FUNCTIONS, EXPRESSION 
AND ATPASE ACTIVITY 
Elena Mattiuzzoa, Roberta Bortolozzia, Giuseppe Bassoa, Giampietro Violaa 
aDipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia, 
Università di Padova, 35131 Padova, Italy 
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2.2 Abstract 
Background 
Failure of cancer chemotherapy can occur through increased efflux of 
chemotherapeutic agents, leading to the reduction of intracellular drug levels and 
consequent drug insensitivity, often to multiple agents. A well-established cause of 
multidrug resistance involves the increased expression of members of the ATP 
binding cassette transporter superfamily, many of which efflux various 
chemotherapeutic compounds from cells. The most extensively characterized MDR 
transporters include ABCB1 (also known as MDR1 or P-glycoprotein), ABCC1 (also 
known as MRP1) and ABCG2 (also known as BCRP or MXR) (6).  
Recent discoveries have provided clear evidence that cancer stem cells are present 
in several cancerous tissues, such as medulloblastoma, neuroblastoma, colon and 
breast cancers. These cancer stem cells represent only a small percentage of total 
cell populations and efficiently efflux Hoechst dye resulting in the dye-negative 
phenotype, also known as side population phenotype. Further investigations revealed 
that Hoechst dye efflux is attributable to increased levels of expression of the MDR1 
and ABCG2 transporters, which are capable of extruding certain chemotherapeutic 
agents, and have been implicated in drug resistance (20). Several approaches have 
been taken to overcome P-gp mediated drug resistance. Recent studies found that 
certain ecdysteroids derivative, such as the most common 20-hydroxyecdysone, 
significantly decrease the resistance of a multi-drug resistant murine leukemia cell 
line expressing the human ABCB1 transporter to doxorubicin. This has prompted 
extensive investigations towards the development of new candidates structures as P-
gp inhibitors.  
Materials and methods 
In this study we examined the effects of new synthetic P-gp inhibitors deriving from 
ecdysteroids alone and in combination with vinblastine (VBL) and doxorubicine 
(DOXO) in lymphoblastic leukemia CEM Vbl-100 and LOVO/DOXO respectively; these 
cells were exposed to VBL and LOVO/DOXO to DOXO, in the presence or absence of 
synthetic ecdysteroids and cell viability was analyzed by the MTT assay. The 
fluorescent dye, rhodamine 123, was used to evaluate the functional activity of the 
P-gp efflux transport system in leukemia and in medulloblastoma cell lines after 
treatment with P-gp inhibitors. Verapamil was used as positive control.  
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We tested this new compounds alone and in combination with cis-platin and 
vincristine also on medulloblastoma cell lines, DAOY and D425, that are enriched in 
cancer stem cells overexpressing P-glycoproteins. 
Results  
In CEM Vbl-100 and LOVO/DOXO, we observed an increase in rhodamine 123 uptake in 
all resistant cell lines upon incubation with the test compounds. In these cells 
synthetic P-gp inhibitors increased the antiproliferative effects of VBL and DOXO and 
combination indexes, calculated by Chou-Talalay method, showed values <1, 
indicating that P-gp inhibitors strongly synergizes with VBL and DOXO. Also in 
medulloblastoma cell lines, P-gp inhibitors synergizes with cis-platin and vincristine. 
Expression levels of P-glycoproteins were quantified by real-time quantitative PCR 
for mRNA levels in CCRF-CEM as control and CEM Vbl-100 treated with synthetic P-gp 
inhibitors. mRNA levels were lower in those cells treated with synthetic P-gp 
inhibitors respect to CEM Vbl-100 control. We investigated the side population cell 
levels in medulloblastoma cell lines after 24 h P-gp inhibitors treatment and we 
found a decrease in SP in all cell lines respect to control and verapamil treatment 
(positive control). 
Conclusions 
These new synthetic P-gp inhibitors could be promising in overcoming multidrug 
resistance in association with standard chemoterapeutic agents and in eradicating 
the side population portion that is one of the most resistant to chemotherapy in solid 
tumours such as medulloblastoma. 
Keywords: P-gp, multidrug resistance, medulloblastoma, ecdysteroids, side 
population 
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2.3 Materials and methods 
Cell culture 
The human leukemia cell line CEM Vbl-100 is a multidrug-resistant line selected 
against vinblastine and supplemented with 100 ng/ml of vinblastine. 
LOVO/DOXO cells are a doxorubicin resistant subclone of LOVO cells and were grown 
in complete Ham’s F12 medium supplemented with doxorubicin (0.1 µg/mL). 
LOVO/DOXO and CEM Vbl-100 were a kind gift of Dr. G. Arancia (Istituto Superiore di 
Sanità, Rome, Italy) (20). 
Medulloblastoma cell lines DAOY and D425 were purchased from the American Type 
Culture Collection. Cells were cultured in RPMI 1640 or DMEM (Life Technologies, 
Italy) supplemented with 10% fetal bovine serμM (FBS), glutamine (2 mM; Life 
Technologies, Italy), penicillin (100 U/ml; Life Technologies, Italy) and streptomycin 
(100 μg/ml; Life Technologies, Italy), and maintained at 37°C in a humidified 
atmosphere with 5% CO2. 
Flow cytometric analysis of rhodamine 123  
Functional activity of P-gp was measured with the fluorescent dye rhodamine 123 
(Rho 123, Pierce, Rockford IL, USA) that is a substrate of P-gp (4). Briefly, after 
different times of treatment, the cells were collected by centrifugation and 
resuspended in Hank's Balanced Salt Solution (HBSS) containing 0.1 μM Rho 123. The 
cells were then incubated for 20 min at 37°C, centrifuged and resuspended in HBSS. 
The fluorescence was directly recorded by flow cytometry with a Coulter Cytomics 
FC500 (Beckman Coulter). 
Flow cytometric analysis of side population  
The protocol of SP analysis was based on Goodell and colleagues. Briefly, cells 
(106/mL) were incubated in DMEM and RPMI containing 2% FCS (Life Technologies) 
and 5 μg/mL Hoechst 33342 dye (Sigma-Aldrich) for 90 min at 37°C, either alone or in 
the presence of 50 μmol/L verapamil (Sigma). At the end of incubation, cells were 
washed and then incubated in PBS supplemented with 2% FCS and 2 μg/mL propidium 
iodide (Sigma), at 4°C for 10 min, to discriminate dead cells. The cells were then 
analyzed in a FACSVantage fluorescence-activated cell sorter (Becton Dickinson) by 
using a dual wavelength analysis (blue, 424–444 nm; red, 675 nm) after excitation 
with 350-nm UV light.  
2.PHARMACOLOGICAL CHARACTERIZATION OF NOVEL P-GP INHIBITORS 
46 
P-glycoprotein activity assay 
P-gp ATPase activity after ecdysteroids treatment was estimated by P-gp-Glo assay 
system (Promega, Madison, WI).  This method relies on the ATP dependence of the 
light-generating reaction of firefly luciferase where ATP consumption is detected as a 
decrease in luminescence. In a 96 well plate, recombinant human P-gp (25 µg) was 
incubated with P-gp-Glo assay bufferTM (20 µl), verapamil (200 µM) as positive 
control, sodium orthovanadate (100 µM) as a P-gp ATPase inhibitor, and test 
compounds (1 μM-10 μM).  The reaction was initiated by addition of MgATP (10 mM), 
then stopped 40 min later by addition of 50 µL of firefly luciferase reaction mixture 
(ATP detection reagent) that initiated an ATP-dependent luminescence reaction. 
Signals were measured 60 min later by Victor3TM 1420 Multilabel Counter 
(PerkinElmer, Waltham, MA, USA).   
Drug treatment 
Cells were grown to 60% confluence and then treated with synthetic P-gp inhibitors 
at a stock concentration of 10 mM, Cells were treated for 72 h using scalar dilutions 
of P-gp inhibitors AL10c and AL23b, combined with vinblastine, doxorubicine, 
vincristine at a stock concentration of 10 mM, cis-platino at a stock concentration of 
5mM (Sigma-Aldrich) and then used at different concentrations. Doxorubicine, 
vincristine and cis-platin were added to drug solutions at fixed combination ratios 
while vinblastine was addes at fixed concentrations of 1 μM. The effectiveness of 
various drug combinations was analyzed by the Calcusyn Version 2.1 software 
(Biosoft). The combination index (CI) was calculated according to the Chou-Talalay 
method (29). A combination index of 1 indicates an additive effect of the 2 drugs. 
Combination index values less than 1 indicate synergy, and combination index values 
more than 1 indicate antagonism. 
MTT assay 
Proliferation was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay after treatment. Equal concentrations of cells were 
plated in triplicate in a 96-well plate and incubated with 10 μl MTT (Sigma-Aldrich, St 
Louis, MO, USA) for 4 h. Absorbance was measured at 560 nm using Victor3TM 1420 
Multilabel Counter (PerkinElmer, Waltham, MA, USA). The growth inhibition50 
(GI50=compound concentration required to inhibit cell proliferation by 50%) was 
calculated by plotting the data as a logarithmic function of (x) when viability was 
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50%. DMSO-treated cells viability was set to 100%. 
RNA isolation and Reverse transcriptase polymerase chain reaction (RT-PCR)  
Total cellular RNA from cell lines and patient bone marrow was extracted with TRIzol 
reagent (Invitrogen). RNA quality was controlled using Nanodrop spectrophotometer. 
Subsequently, 1 μg of total RNA was reversely transcribed using random hexamers 
and Superscript II (Invitrogen), according to the manufacturer’s instructions. 
Real time PCR 
Real-time quantitative (RQ-PCR) was performed on an Applied Biosystems 7900 HT 
Sequence Detection System using SYBR Green PCR Master Mixture Reagents (Applied 
Biosystems; Forest City, CA. Primer used for analysis were for ABCB1 gene (p-
glycoprotein). All expression values were normalized using expression of GUS as an 
endogenous control (Table 1). 
Table 1. 
Statistical analysis 
All experiments were performed with a minimum of three technical and three 
biological replicates, and values reported are the mean of the three biological 
replicates, unless otherwise indicated. Error bars represent the standard deviation 
(SD) from the mean, unless otherwise indicated. All statistical analyses were 
performed using the GraphPad Prism software. 
 Forward Reverse 
ABCB1 5’- CACCAAGGCCCTGCGCTACC -3’  5’- ACACCCGGTACCCGCGATGA -3’ 
GUS 5’-GAAAATATGTGGTTGGAGAGC-3’  5’-CGAGTGAAGATCCCCTTTTTA-3’ 
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2.4 Results 
Antiproliferative effect of new synthetic ecdysteroids on ABCB1 overexpressing 
drug-selected cell lines 
To explore the effect of these new synthetic ecdysteroids we choose CCRF CEM as 
wild type cells and CEM Vbl-100 as ABCB1 overexpressing cell lines. Cells were 
exposed to 13 synthetic ecdysteroids (Fig.4a) for 72 h at concentrations ranging from 
0.001 to 100 μM. We treated also with vinblastine to verify the resistance or 
sentitivity in CEM Vbl-100 and wild type cell line respectively. The GI50 measured by 
MTT assay after 72 h was in the micromolar range for all cell lines treated as shown 
in Fig.4b: GI50 of CEM Vbl-100 is lower respect to GI50 of CCRF CEM cell line for many 
of the compounds investigated in particular compounds AL10c, AL23b, AL26 and 
PON3 showd the lowest GI50 in this resistant cell line.   
AL05a 
 
AL09b 
 
AL10c 
 
AL23b 
 
AL26 AL05b 
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Fig. 4a Structure of new 13 synthetic ecdysteroids. 
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Fig. 4b In vitro cell growth inhibitory effects of ecdysteroid compounds against CCRF-CEM 
and CEM Vbl-100 cell line. GI50= compound concentration required to inhibit tumour cell 
proliferation by 50%. Data are expressed as the mean ± SE from the dose-response curves of 
at least three independent experiments. 
Rhodamine 123 accumulation in CEM Vbl-100 and LOVO/DOXO cells 
Rhodamine 123 (Rho123) has been known to be substrate for P-gp, that could be used 
to determine whether the ecdysteroids modulate intracellular drug levels by 
inhibiting P-gp function. The accumulation of Rho123 was determined using flow 
cytometry. We performed a first rho123 analysis with those ecdysteroids that had the 
lower GI50 to understand their activity on the accumulation of rho123 in CEM Vbl-100 
cell line. As shown in Fig.5 there is a stronger intracellular accumulation of Rho123 
in correspondence of cells treated with AL10c and AL23b for two hours; for this 
reason, we choose these two compounds for successive analysis. 
Fig. 5 Rhodamine123 accumulation in CEM Vbl-100 cell line. Cells were treated with the 
indicated concentration of AL10c, AL23b, AL26, AL29 (1 and 10 μM), 25 and 50 μM verapamil 
(positive control). Inhibitors were incubated for 2 h; then, Rho123 was added and cells were 
incubated for 30 min at 37° in the dark. Cells were then harvested and used immediately to 
measure Rho123 fluorescence using Beckman Coulter FC500. 
It was found that new synthetic ecdysteroids, AL10c and AL23b, dramatically 
increased Rho123 accumulation in CEM Vbl-100 cells; verapamil, known to fully 
inhibit P-gp activity, was used as positive control at 25 µM concentration. As shown 
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in Fig.6A the accumulation was enhanced when the cells were treated for 2 hours 
with 10 μM of AL10c and AL23b respect to control and verapamil. In LOVO/DOXO 
cells (Fig.6B), we used doxorubicine as substrate for P-gp at the concentration of 1 
µM, and also in this case we found that there was an accumulation of doxorubicine in 
those cells treated with 10 µM of AL10c and AL23b for 4 hours; verapamil was used 
as positive control at 25 µM concentration. 
A) 
 
             Rhodamine123 
Fig. 6 Effect of new synthetic 
ecdysteroids on the accumulation of 
Rho123 in CEM Vbl-100 and of 
Doxorubicine in LOVO/DOXO cells. 
Cells were treated with the indicated 
concentration of AL10c and AL23b 
(10 μM) and 25 μM verapamil (positive 
control). A) In CEM Vbl-100, inhibitors 
were incubated for 2 h; then, Rho123 
was added and cells were incubated for 
30 min at 37° in the dark. Cells were 
then harvested and used immediately 
to measure Rho123 fluorescence using 
Beckman Coulter FC500; b) In 
LOVO/DOXO cell line, inhibitors were 
incubated for 4h; then, doxorubicine 
was added and cells were incubated for 
15 min at 37° in the dark. Cells were 
then harvested and used immediately 
to measure doxorubicine fluorescence 
using Beckman Coulter FC500. 
B) 
 
                Doxorubicine 
Modulation of P-gp ATPase activity with new synthetic ecdysteroids compounds 
The Pgp-Glo™ Assay Systems permit to perform luminescent P-gp ATPase assays. 
Compounds that interact with P-gp can be identified as stimulators or inhibitors of its 
ATPase activity. Through this assay we examined the effects of new ecdysteroids on 
drug-stimulated P-gp ATPase activity. This approach is primarily used to characterize 
inhibitors of P-gp ATPase activity. Reduction of drug-stimulated ATPase activity by a 
23b 10 μM
10c 10 μM 
Verapamil 25 μM 
Control 
23b 10 μM
10c 10 μM 
Doxorubicine 1 μM 
Verapamil 25 μM 
Control 
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compound indicates it is a Pgp ATPase inhibitor.  
We examined the effects of AL10c and AL23b of inhibiting the P-gp ATPase activity 
on recombinant human Pgp in a cell membrane fraction. As positive control, we used 
Verapamil that is the most known inhibitor of P-gp. Our preliminary results suggest 
that AL10c and AL23b inhibit the P-gp ATPase activity in a stronger way and at 
lower concentration respect to Verapamil (Fig.7). 
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Fig. 7 New synthetic ecdysteroids compounds inhibit P-gp ATPase activity. 
Treatment with AL10c and AL23b decreases P-gp expression in CEM Vbl-100 
To further test the efficacy of synthetic ecdysteroids treatment and to assess the 
therapeutic role of P-gp inhibition in the treatment of MDR, we treated CEM Vbl-100 
with AL10c and AL23b 10 µM and with verapamil 50 µM as positive control. We 
analyzed the effects of this treatment at transcriptional level after 24h to explore if 
these new compounds could induce a decrease in P-gp mRNA. Quantitative real time 
PCR showed a significative downregulation of P-gp expression in CEM Vbl-100 treated 
with AL10c and AL23b respect to control sample (Fig.8). 
These results suggest that pharmacological inhibition of P-gp could be promising in 
the treatment of MDR. 
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Fig. 8 Real-time PCR analysis of P-gp expression in multidrug resistant CEM vbl-100. Cells 
were treated with AL10c and AL23b 10 µM, and verapamil 50 µM for 24 h; P-gp expression 
was quantified and normalized on GUS expression, used as an internal control. The P-gp/GUS 
ratio for untreated samples was set as a baseline value to which all transcript levels were 
normalized. Error bars refer to standard deviations for three independent experiments. 
Statistical analysis was performed using ANOVA multicomparison test against the cells treated 
with the non-treated control; ** p ≤ 0.05. 
Synthetic ecdysteroids compounds synergize with Vinblastine in CEM Vbl-100 
cell line and with Doxorubicine in LOVO/DOXO cell line 
Because AL10c and AL23b inhibited P-gp efflux activity, we examined their effect on 
vinblastine-induced cytotoxicity to evaluate if there could be a synergistic effect in 
the citotoxicity effect of vinblastine. In drug-resistant CEM Vbl-100 cells, co-
incubation of vinblastine at fixed concentration of 1 μM with AL10c and with AL23b 
resulted in a significant increase in the cytotoxicity of vinblastine (Fig.9A-B). In this 
experiment, AL10c and AL23b were added in a concentration range of 0.001-100 μM. 
We found that both synthetic ecdysteroids synergise with vinblastine with a 
combination index <1 (Fig.9C). 
We also performed drug combination experiments in LOVO/DOXO cell line using 
AL10c and AL23b in combination with Doxorubicine. Cells were treated at fixed 
combination ratio (1:10): AL10c and AL23b were added in a concentration range of 
0.001-100 μM and Doxorubicine in a molar range of 0.0001-10 μM; also in this case we 
found a combination index <1 indicating a synergistic effect between our synthetic 
ecdysteroids and Doxorubicine (Fig.9d Supp. Materials). 
In all experiments cell viability was assessed by MTT test after 72 hours of 
incubation.  
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Fig. 9 Effect of AL10c and AL23b treatment alone and in combination with vinblastine in 
CEM Vbl-100 cells. A), B) Cells were treated at the indicated concentration and cell viability 
was assessed by MTT test after 72 hours of incubation. Data are expressed as mean ± SEM of 
three independent experiments. C) Combination index values (CI) in CEM Vbl-100 cell line 
treated with AL10c and AL23b in combination with vinblastine. 
Synthetic ecdysteroids compounds synergize with cis-platin and vincristine in 
Medulloblastoma cell lines 
In order to assess if these new synthetic ecdysteroids could increase the efficacy of 
standard medulloblastoma chemotherapy, we tested if they can be used in 
combination with the most commonly used chemotherapeutics.  To this end, two 
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different medulloblastoma cell lines, DAOY and D425 were treated with AL10C and 
AL23b in combination with chemotherapeutic agents (cis-platin and vincristine) used 
normally to treat pediatric medulloblastoma patients. More specifically, as shown in 
Fig.10a in DAOY cell line, AL10c and AL23b synergize with chemotherapeutic drugs, 
causing a synergistic increase of their cytotoxicity; AL10c and AL23b were combined 
with different drugs at fixed molar combination ratio, and cell viability analyzed by 
MTT assay after 72 h. 
As demonstrated by the values of combination index (CI) according to Chou and 
Talalay (20, 21) (Fig.10b), ED50 in DAOY cell line, AL10c and AL23b in combination 
with chemotherapeutic drugs acted in a synergistic fashion (CI<1). 
Our results show that in general, the pharmacological inhibition of P-gp activity 
caused by AL10c and AL23b, can significantly increase the cell death effects 
provoked by the treatment with the conventional chemotherapeutic agents used 
alone. 
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Fig. 10a Effect of AL10c and AL23b treatment in combination with different 
chemotherapic drugs in DAOY cells. A), B) Cells were treated at the indicated concentration 
and at fixed combination ratio; AL10c and AL23b (0.001-100 μM), vincristine (0.001-100 nM) 
and cis-platin (0.0001-10 μM); viability was assessed by MTT test after 72h of incubation. Data 
are expressed as mean ± SEM of three independent experiments. 
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Fig. 10b Effect of AL10c and AL23b treatment in combination with different 
chemotherapic drugs in DAOY cells. Combination index values (CI) in DAOY cell line treated 
with AL10c and AL23b in combination with Vincristine and Cis-platin. 
For what concern D425 cell line, AL10c and AL23b were combined with different 
drugs at fixed molar combination ratio, but in this case, AL10c synergizes with 
vincristine and cis-platin, causing a synergistic increase of their cytotoxicity while 
AL23b sinergyzes only with vincristine but not with cis-platin (Fig.10d Supp. 
Materials); as demonstrated by the values of combination index (CI) according to 
Chou and Talalay (20, 21) (Fig.10e) in D425 cell line, AL10c and AL23b in 
combination with chemotherapeutic drugs acted in a synergistic fashion (CI<1). 
Effect of AL10c and AL23b on the side population subset in Medulloblastoma cell 
lines 
We investigated the presence of side population in DAOY cell line. Following staining 
with Hoechst 33342, a SP was identified as a distinct tail extending from the main 
population with the characteristic low fluorescent profile in dual wavelength 
analysis. 
We treated DAOY cell line with AL10c and AL23b 10 μM for 2 h and with Verapamil 
50 μM, as an SP cell control in the Hoechst efflux, which blocks transporters of the 
ABC family and abrogates the ability of cells to efflux the Hoecst dye. 
As shown in Fig.11 SP disappears in those cells treated with AL10c and AL23b 
respect to control and Verapamil. 
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Fig. 11 Effect of AL10c and AL23b on the SP subset in DAOY cell line. A), B), C), D) The 
diagrams show representative analysis of the SP subpopulation in DAOY cell line treated with 
AL10c and AL23b 10 μM and then compared with verapamil 50 μM treated and untreated 
cells. Analysis was carried out after 2 h of treatment. E) Hystogram shows the percentage of 
side population in DAOY cell line. 
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2.5 Discussion 
Drug resistance is a significant factor that limits the effectiveness of current 
chemotherapeutic drugs. In an attempt to overcome the resistance that can develop 
due to P-gp overexpression, P-gp inhibitors have been developed. Numerous clinical 
trials evaluating the effects of verapamil or valspodar in combination with 
chemotherapeutic agents such as doxorubicin, vincristine, dexamethasone, 
cyclophosphamide, paclitaxel have shown that patients given concurrent 
administration of P-gp inhibitors with chemotherapeutic agents have an increased 
toxicity and show modest or no increase in survival These results provide insight into 
an important limitation of P-gp inhibitors and suggest the importance of considering 
the development of new P-gp inhibitors. 
In this study, we evaluated how new synthetic P-gp inhibitors reverse multidrug 
resistance in induced resistant leukemia cell line and in medulloblastoma.  
In resistant leukemia cell lines CEM Vbl-100 and LOVO/DOXO both AL10c and AL23b 
were able to increase two P-g substrates, that are efficiently pumped out of tumour 
cells where P-gp is highly expressed: -rhodamine 123 and -doxorubicine respectively. 
Direct comparison with Verapamil, known to fully inhibit P-gp activity, demonstrated 
that AL10c and AL23b, at lower concentration, are more potent respect to 
Verapamil. Importantly the two drugs have shown lower toxicity in wild cells 
suggesting a preferential effect toward MDR cells.  
In addition, these studies clearly indicated that reversal of multidrug resistance by 
AL10c and AL23b was through selective inhibition of P-gp function: in contrast to 
the modulatory activity in the resistant cell lines, AL10c and AL23b had no 
significant effect on cytotoxic drug activity in non P-gp-expressing parental cell lines 
(CEM and LOVO).  
To understand the mechanisms of P-gp inhibition by AL10c and AL23b, P-gp ATPase 
activity and P-gp mRNA expression were further studied. Since the efflux function of 
ABC transporters is ATP-dependent, measuring ATPase activity is another approach to 
study the inhibition of ABC transporters. We tested AL10c and AL23b in comparison 
with Verapamil, used as positive control; at 1 and 10 μM our compounds showed a 
significant inhibitory effect on P-gp ATPase activity respect to Verapamile 200 μM. 
RT-PCR analysis revealed that relative ABCB1 mRNA expression was down-regulated 
by AL10c and AL23b after 24h treatment of resistant cell line CEM Vbl-100.  
AL10c and AL23b were found to apparently reverse multidrug resistance in P-gp 
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overexpressing leukemia cells.  We determined the multidrug resistance reversing of 
CEM Vbl-100 and LOVO/DOXO cell lines. It was found that AL10c and AL23b 
markedly increased the sensitivity of CEM Vbl-100 cell line to vinblastine and of 
LOVO/DOXO cell line to doxorubicine. 
In conclusion, the first part of this study evaluated the inhibition of P-gp function in 
resistant leukemia cells by novel synthetic ecdysteroids  
The primary treatment of Medulloblastoma consists of maximal tumour resection 
followed by craniospinal radiotherapy and chemotherapy. Several chemotherapeutic 
agents, including vincristine and cis-platin have been used against aggressive 
neoplasms. However, cancer cells usually develop resistance to conventional 
chemoterapeutics and radiation, which limits the therapeutic effectiveness of these 
drugs (23). In some cases, chemoresistance may result in the survival of a population 
of tumour cells that subsequently leads to recurrence following treatment (24). This 
may be particularly true for tumours that are composed of a heterogeneous 
population of cells such as Medulloblastoma. Within this population of cells there is 
side population that exhibits chemoresistance related to the ABC transporter. 
In this study we clearly demonstrate that our new synthetic ecdysteroids 
synergistically reverse resistance to cis-platin and vincristine; in addition, they 
dramatically decrease the percentage of side population respect to the untreated 
cells and Verapamil used at higher concentration (50 μM) respect to our derivatives. 
In conclusion, these new compounds may be considered as promising candidates as P-
gp inhibitors and they could be used as an adjuvant therapy together with the 
current chemotherapies in cancer treatment, in particular to those cancers with P-
gp-mediated multidrug resistance. 
2.PHARMACOLOGICAL CHARACTERIZATION OF NOVEL P-GP INHIBITORS 
60 
2.6 Supplementary materials 
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Fig. 9d Effect of AL10c and AL23b treatment in combination with Doxorubicine in 
LOVO/DOXO cell line. A), B) AL10c and AL23b were added in a concentration range of 0.001-
100 μM and Doxorubicine in a molar range of 0.0001-10 μM. Cell viability was assessed by MTT 
test after 72 hours of incubation. Data are expressed as mean ± SEM of three independent 
experiments. C) Combination index values (CI) in LOVO/DOXO cell line treated with AL10c and 
AL23b in combination with Doxorubicine. CI is <1 indicating a synergistic effect between our 
synthetic ecdysteroids and Doxorubicine. 
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Fig. 10d Effect of AL10c and AL23b treatment in combination with different 
chemotherapic drugs in D425 cells. Cells were treated at the indicated concentration and at 
fixed combination ratio; AL10c and AL23b (0.001-100 μM), vincristine (0.001-100 nM) and cis-
platin (0.0001-10 μM); viability was assessed by MTT test after 72h of incubation. Data are 
expressed as mean ± SEM of three independent experiments. 
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Fig. 10e Combination index values (CI) in D425 cell line treated with AL10c and AL23b in 
combination with Vincristine and Cis-platin. CI is <1 indicating a synergistic effect between 
our synthetic ecdysteroids and chemoterapeutic drugs. 
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3.1 General introduction 
Compared to the normal counterpart, cancer cells are characterized by the cell cycle 
deregulation that leads to their hyperproliferative pattern. Tumour cells accumulate 
mutations that result in unscheduled proliferation, as a consequence of 
unresponsiveness to growth inhibitory signals, self-sufficiency in growth factors or 
both. Therefore, several antitumoural strategies have been proposed for targeting 
the cell division cycle in cancer by targeting tubulin polymerization (1). 
There has been in recent years an intense effort directed at the discovery and 
development of novel small molecules, many of which are natural products, able to 
interfer with tubulin polymerization because of their anti-cancer potential (2). 
3.1.1 Tubulin structure 
Microtubules are a dynamic cellular compartment in both neoplastic and normal 
cells. The microtubule system of eukaryotic cells plays important roles in regulating 
cell architecture and has an essential role in cell division, since microtubules are a 
key component of the mitotic spindle (3). This dynamicity is characterized by the 
continuous turnover of -tubulin heterodimers in the polymeric microtubules. 
Because of their key roles in cell structure and cell division, they are involved in a 
variety of fundamental cellular functions, such as cell formation, maintenance of cell 
shape, regulation of motility, cell signaling, secretion, intracellular transport and 
mitotic spindle elongation for the correct chromosome segregation (4). 
Microtubules are built from subunits, each of which is itself a dimer composed by two 
very similar globular proteins called α-tubulin and β-tubulin (5). The tubulin dimers 
stack together by non-covalent bonding to form the wall of the hollow cylindrical 
microtubules. This tube like structure is made of 13 parallel protofilaments, which 
are linear chains of tubulin dimers with α and β-tubulin alternating along its length.  
Each protofilament has a structural polarity, with α-tubulin exposed at one end and 
β-tubulin at the other, and this polarity is the same for all protofilaments, giving a 
structural polarity to the microtubule as a whole. One end of the microtubule, 
thought to be the β-tubulin end, is called plus end, and the other, the α tubulin end 
is called minus end.  
The microtubule system has a dynamic behavior, known as “dynamic instability”, in 
which microtubules alternate between period of growing and shrinking through the 
addition or removal of tubulin monomers. This process is mediated by hydrolysis of 
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GTP: β-tubulin has binding site for GTP and microtubule stability depend on the rate 
of GTP/GDP-bound tubulin. If new GTP molecules are added more rapidly than GTP is 
hydrolyzed, the microtubules retain a GTP-cap and growth continues. However, if 
the rate of polymerization is slow, GTP is hydrolyzed to GDP, GDP-bound tubulin 
dissociates resulting in a rapid depolymerization of microtubules (Fig.1). Dynamic 
instability is one of the key events of the cell cycle: during interphase microtubules 
turnover is slow but becomes rapid at the onset of mitosis with the disassembly of 
microtubules network, followed by the formation of a new network of spindle 
microtubules, that can turover 4-100 times more rapidly than interphase 
microtubules (6). 
Fig. 1  The microtubule structure is composed by   and -tubulin heterodimers (7). 
The regulation of microtubules dynamics, temporal and spatial organization is a 
tightly regulated mechanisms to ensure the correct spindle formation and 
segregation of chromosomes during cell division. The main regulators of microtubules 
dynamics are the microtubule-sequestring protein stathmin (STMN) and microtubules-
associated proteins (MAPs). Stathmin is a cytosolic phosphoprotein that regulates 
mitotic spindle by binding to tubulin heterodimers and inducing microtubule 
destabilization, while MAPs proteins can bind and stablize microtubules against 
depolymerization (6). 
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3.1.2 Tubulin targeting agents 
Microtubules are extremely important in the process of mitosis, during which the 
duplicated chromosomes of a cell are separated into two identical sets before 
cleavage of the cell into two daughter cells. Their importance in mitosis and cell 
division makes microtubules an important target for anticancer drugs. In the context 
of cancer, the tubulin family of proteins is recognized as the target of the tubulin-
binding chemotherapeutics, which suppress the dynamics of the mitotic spindle to 
cause mitotic arrest and cell death.  
Microtubules may function to coordinate stress responses across the cell, resulting in 
enhanced cell survival in the harsh tumour microenvironment, resistance to 
chemotherapy treatment, and the development of more aggressive disease (8). 
The tubulin-binding agents (TBA) are a very successful class of cancer drugs with 
therapeutic benefits in both hematopoietic and solid tumours, A large number of 
natural agents and/or their analogues bind to soluble tubulin and/or directly to 
tubulin in the microtubules. Most of these compounds are antimitotic agents that 
inhibit cell proliferation by acting on the polymerization dynamics of spindles, which 
are essential to proper spindle function of microtubules (9). Disruption of 
microtubule blocks cell cycle progression in many cells at the transition from 
prometaphase/metaphase to anaphase; this phenomenon is called the mitotic 
checkpoint. Cell cycle arrest at the mitotic checkpoint is activated by a number of 
defects in microtubule-kinetochore interactions including microtubule 
depolymerization, stabilization of microtubule dynamics, absence of tension on 
kinetochore microtubules, and the presence of kinetochores that are not attached to 
microtubules (10). There are many chemically diverse compounds that bind to the 
tubulin–microtubule system. They are broadly classified into two groups: one group 
called microtubule-stabilizing  that stimulates microtubule polymerization (such as 
taxanes and epothilones) and one group knonwn as microtubule-destabilizing that 
 inhibits microtubule polymerization at high concentrations (such 
as vincristine, vinblastine, vinorelbine, colchicine, combretastatins) drugs (Fig.2) 
(11). 
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Fig. 2 Antimitotic drugs binds to microtubule at diverse sites. A) Vinblastine binds at the 
microtubule plus end suffice to suppress microtubule dynamics; b) colchicine forms 
complexes with tubulin dimers and copolymerizes into the microtubule lattice, suppressing 
microtubule dynamics; c) paclitaxel binds along the interior surface of the microtubule, 
suppressing its dynamics (12). 
The mechanisms that determine sensitivity or resistance to anti-mitotic agents that 
target tubulin are not well understood. Studies addressing how the various cellular 
events associated with cell fate following TBA treatment are influenced by tubulin 
isotype composition might reveal new information on drug sensitivity. There are 
multiple α- and β-tubulin isotypes that are encoded by different genes, located on 
different chromosomes and that have tissue and cell-specific expression patterns. 
The structure of tubulin has been highly conserved throughout evolution, and tubulin 
isotypes share a high degree of aminoacid homology but are distinguished by their 
unique carboxy-terminal tails (the last 20–27 amino acids). These tubulin isotypes can 
undergo post-translational modifications, which can alter the interaction of 
microtubules with microtubule associated proteins and change their function (13). 
Understanding the molecular mechanisms that mediate resistance to tubulin-binding 
agents will be vital to improve the efficacy of these agents. 
3.1.3 Citotoxic effect of tubulin binding agents 
Both classes of antimitotic drugs suppress microtubule dynamics causing alteration in 
the spindle organization, with a delay or a block at the metaphase-anaphase 
transition during mitosis with consequent G2-M cell cycle arrest. Furthermore, 
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activation of spindle assembly checkpoint in G2 phase and prolonged mitotic arrest 
provoke apoptosis induction (14). The apoptosis is a programmed cell death 
characterized by chromatin condensation, DNA fragmentation and activation of 
caspases. The apoptotic process could be triggered by two pathways called extrinsic 
and intrinsic pathway. Several works describe that tubulin binding agents induce 
apoptosis mainly through the intrinsic pathway activation, characterized by the 
alteration of mitochondrial parameters (such as alteration of membrane potential 
and ROS production). However, how cell death induction correlates with microtubule 
destabilization and mitotic arrest still remains unclear and controversial.  
The intrinsic pathway of apoptosis is mainly initiated by the release of cytochrome c 
from the mitochondrion. Upon release into the cytoplasm, cytochrome c associates 
with dATP, procaspase-9, and the adaptor protein APAF-1, leading to the sequential 
activation of caspase-9 and effector caspases (15). 
The release of apoptosis-inducing proteins from the mitochondria is regulated by pro- 
and antiapoptotic members of the Bcl-2 family. Antiapoptotic members (Bcl-2, Bcl-
XL, and Mcl-1) associate with the mitochondrial outer membrane via their carboxy 
termini, exposing to the cytoplasm a hydrophobic binding pocket composed of Bcl-2 
homology (BH) domains 1, 2, and 3, that is crucial for their activity. Perturbations of 
normal physiologic processes in specific cellular compartments lead to the activation 
of BH3-only proapoptotic family members (such as Bad, Bim, Bid, Puma, Noxa, and 
others). This leads to the altered conformation of the outer-membrane proteins Bax 
and Bak, which then oligomerize to form pores in the mitochondrial outer membrane 
resulting in cytochrome c release. Therefore, the relative levels of expression of 
antiapoptotic Bcl-2 family members compared to the levels of proapoptotic BH3-only 
proteins at the mitochondrial membrane determines the activation state of the 
intrinsic pathway. It has been demonstrated that many microtubules binding agents 
can induce phosphorylation in serine residues of Bcl2 antiapoptotic proteins, in cell 
that are blocked in G2-M phase, leading to loss prosurvival function and to 
destabilization of mitochondrial potential. Moreover, Bcl2 phosphorylation decreases 
its binding to the proapoptotic Bax protein, resulting in an increase of free Bax and 
apoptosis (16). 
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3.2 Aim of the project 
The microtubule system plays an essential role on a variety of cellular processes, 
such as on maintaining of cell shape, intracellular transport and more importantly on 
cell cycle division. Therefore, over the years several antitumoural compounds have 
been developed for targeting tubulin polymerization and thus cell cycle progression 
in cancer.  
Among the synthetic inhibitors of tubulin polymerization, we previously described the 
synthesis and biological characterization of two series of compounds based on the 2-
alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)benzo[b]thiophene and thieno[2,3-
b]pyridine molecular skeletons (compounds with general structure 2 and 3, 
respectively) that showed strong antiproliferative activity against a panel of cell lines 
and act as inhibitors of microtubule polymerization by interfering with the colchicine 
site of tubulin. To investigate the possible binding mode for this series of compounds, 
we performed a series of molecular docking simulations in the colchicine site.  
Based on these observations, a new series of derivatives with general formulae 4 was 
designed with the aim to improve their antimitotic activity. 
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3.3 Abstract 
Microtubules are recognized as crucial components of the mitotic spindle during cell 
division, and, for this reason, the microtubule system is an attractive target for the 
development of anticancer agents.  
Continuing our search strategy for novel tubulin targeting-compounds, a new series 
of 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)-5-aryl/heteroaryl thiophene 
derivatives was designed, synthesized and demonstrated to act as tubulin 
polymerization inhibitors at the colchicine site.  A structure-activity relationship 
study on the phenyl at the 5-position of the thiophene ring was performed by 
introducing a variety of substituents containing electron-releasing and electron-
withdrawing groups, with the 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino) 
thiophene scaffold being the minimum structural requirement for activity.  
Of the tested compounds, derivatives 4a, 4c, 4i and 4k, possessed the highest 
overall potency and displayed high antiproliferative activities at submicromolar 
concentrations, with IC50 values ranging from 0.13 to 0.84 M against four different 
cancer cell lines. Three agents (4a, 4c and 4i) in the present series had similar 
effects, and these were comparable to those of reference compound combretastatin 
A-4 (CA-4), especially as inhibitors of tubulin assembly. The antitubulin effects 
correlated with the cytostatic activities and indicate that these compounds inhibit 
cell growth through inhibition of tubulin polymerization by binding at the colchicine 
site. Compound 4c, containing the thien-2’-yl ring at the 5-position of the 2-
methoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene scaffold, exhibited 
substantial antiproliferative activity with a mean IC50 value of 140 nM, inhibited 
tubulin polymerization with an IC50 value of 1,2 M, similar to that of CA-4 (IC50: 1,1 
M), and induced apoptosis in HeLa cells. 
Keywords: microtubule, tubulin polymerization inhibitors, antiproliferative agents, 
colchicine site, structure-activity relationship. 
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3.4 Materials and methods 
 Cell culture  
All cell lines were purchased from the American Type Culture Collection. Murine 
leukemia L1210, murine mammary carcinoma FM3A, human T-lymphocyte leukemia 
CEM were cultured in RPMI 1640 (Life Technologies, Italy) and human cervix 
carcinoma (HeLa) was cultured in DMEM (Life Technologies, Italy). All mediums were 
supplemented with 10% fetal bovine serum (FBS), glutamine (2 mM; Life 
Technologies, Italy), penicillin (100 U/ml; Life Technologies, Italy) and streptomycin 
(100 μg/ml; Life Technologies, Italy), and maintained at 37°C in a humidified 
atmosphere with 5% CO2.  
Peripheral blood lymphocytes (PBL) from healthy donors were obtained by separation 
on Lymphoprep (Fresenius KABI Norge AS) gradient. After extensive washing, cells 
were resuspended (1.0 x 106 cells/mL) in RPMI-1640 with 10% fetal bovine serum and 
incubated overnight. For cytotoxicity evaluations in proliferating PBL cultures, non-
adherent cells were resuspended at 5 x 105 cells/mL in growth medium, containing 
2.5 µg/mL PHA (Irvine Scientific), whereas for cytotoxicity evaluations in resting PBL 
cultures, non-adherent cells were resuspended (5 x 105 cells/mL). Different 
concentrations of the test compounds were added, and viability was determined 72 h 
later by the MTT test. 
MTT assay 
Proliferation was assessed by MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazoliuM bromide) assay after treatment. Cells were suspended at 300,000-
500,000 cells/mL and plated in triplicate in a 96-well plate. After incubation at 37°C 
for two (L1210 and FM3A), three (CEM) or 4 days (HeLa), 10 μl of MTT was added 
(Sigma-Aldrich, St Louis, MO, USA) for 4 h. Absorbance was measured at 560 nm using 
Victor3TM 1420 Multilabel Counter (PerkinElmer, Waltham, MA, USA). The growth 
inhibition 50 (GI50=compound concentration required to inhibit cell proliferation by 
50%) was calculated by plotting the data as a logarithmic function of (x) when 
viability was 50%. DMSO-treated cells viability was set to 100%. 
Effects on tubulin polymerization and on colchicine binding to tubulin  
To evaluate the effect of the compounds on tubulin assembly in vitro (17), varying 
concentrations of compounds were preincubated with 10 M bovine brain tubulin in 
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0.8 M monosodium glutamate (pH adjusted to 6.6 with HCl in a 2 M stock solution) at 
30˚C and then cooled to 0˚C. After addition of 0.4 mM GTP, the mixtures were 
transferred to 0C cuvettes in a recording spectrophotometer and warmed to 30°C. 
Tubulin assembly was followed turbidimetrically at 350 nm. The IC50 was defined as 
the compound concentration that inhibited the extent of assembly by 50% after a 20 
min incubation. The capacity of the test compounds to inhibit colchicine binding to 
tubulin was measured as described (18). The reaction mixtures contained 1 M 
tubulin, 5 M [3H]colchicine and 5 M test compound. 
 Molecular modeling  
All molecular modeling studies were performed on a MacPro dual 2.66 GHz Xeon 
running Ubuntu 14.04. The tubulin structure was downloaded from the PDB data bank 
(http://www.rcsb.org/; PDB code 1SA0) (19). Hydrogen atoms were added to the 
protein, using the Protonate 3D routine of the Molecular Operating Environment 
(MOE) (Molecular Operating Environment (MOE 2015.10); Chemical Computing Group, 
Inc; Montreal, Quebec, Canada, 2015; http://www.chemcomp.com.).Ligand 
structures were built with MOE and minimized using the MMFF94x force field until a 
RMSD gradient of 0.05 kcal mol-1 Å-1 was reached. The docking simulations were 
performed using PLANTS. 
Annexin V/Pi assay  
Surface exposure of phosphatidylserine on apoptotic cells was measured by flow 
cytometry with a Coulter Cytomics FC500 (Beckman Coulter) by adding Annexin V 
conjugated to fluorescein isothiocyanate (FITC) to cells according to the 
manufacturer's instructions (Annexin V Fluos, Roche Diagnostic). Simultaneously, the 
cells were stained with PI. Excitation was set at 488 nm, and the emission filters 
were at 525 and 585 nm, respectively, for FITC and PI.  
Flow cytometric analysis of cell cycle distribution  
Cell cycle distribution was measured by flow cytometry with a Coulter Cytomics 
FC500 (Beckman Coulter) by using propidium iodide in propidium iodide/RNase A 
staining. 5 × 105 HeLa cells were treated with different concentrations of the test 
compounds for 24 h. After the incubation period, cells were harvested, washed with 
phosphate-buffered saline solution (PBS) and fixed in 70% EtOH overnight at 4°C. 
After fixation, cells were washed twice with PBS before resuspension in 0.1% Triton 
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X-100/propidium iodide/RNase A solution (1mg/mL of PI and 4mg/mL RNase-A). Cells 
were incubated at room temperature in the dark light for 30 min and then processed 
for analysis. Samples were analyzed on a Cytomic FC500 flow cytometer (Beckman 
Coulter). DNA histograms were analyzed using MultiCycle for Windows (Phoenix Flow 
Systems). 
Analysis of mitochondrial potential and reactive oxygen species (ROS) 
The mitochondrial membrane potential was measured with the lipophilic cation JC-1 
(Molecular Probes, Eugene, OR, USA), while the production of ROS was followed by 
flow cytometry using the fluorescent dye H2DCFDA (Molecular Probes), as previously 
described (20). 
Immunoblot analysis 
HeLa cells were incubated in the presence of 4c and, after different times, were 
collected, centrifuged, and washed two times with ice-cold phosphate buffered 
saline (PBS). The pellet was then resuspended in lysis buffer. After the cells were 
lysed on ice for 30 min, lysates were centrifuged at 15,000 x g at 4°C for 10 min. The 
protein concentration in the supernatant was determined using the BCA protein assay 
reagents (Pierce, Italy). Equal amounts of protein (10 μg) were resolved using sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Criterion Precast, 
BioRad, Italy) and transferred to a Immobilon-P membrane (Millipore). Membranes 
were blocked with a bovine serum albumin solution (3% in Tween PBS 1X) for at least 
2 h at room temperature. Membranes were then incubated with primary antibodies 
against Bcl-2, PARP, cdc25c, cyclin B, p-cdc2Tyr15, Mcl-1 (all from Cell Signaling) and 
-actin (Sigma-Aldrich) and gently rotated overnight at 4°C. Membranes were next 
incubated with peroxidase labeled secondary antibodies for 60 min. All membranes 
were visualized using ECL Select (GE Healthcare), and images were acquired using an 
Uvitec-Alliance imaging system (Uvitec, Cambridge, UK). To ensure equal protein 
loading, each membrane was stripped and reprobed with anti-β-actin antibody. 
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3.5 Results 
3.5.1 Molecular modelling 
Among the synthetic inhibitors of tubulin polymerization, we previously described the 
synthesis and biological characterization of two series of compounds based on the 2-
alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)benzo[b]thiophene and thieno[2,3-
b]pyridine molecular skeletons (compounds with general structure 2 and 3, 
respectively) that showed strong antiproliferative activity against a panel of cell lines 
and act as inhibitors of microtubule polymerization by interfering with the colchicine 
site of tubulin (21). To investigate the possible binding mode for this series of 
compounds, we performed a series of molecular docking simulations in the colchicine 
site. The results obtained showed that the trimethoxyphenyl unit of these compounds 
is placed in proximity of Cys241. Furthermore, the formation of an intramolecular 
hydrogen bonding interaction between the anilino and the carbonyl groups in these 
series of molecules allows the formation of a hydrogen bond between the ester itself 
and Ala250. This study indicated that important structural requirements that play a 
crucial role in enhancing anti-microtubule activity are the presence of an 
alkoxycarbonyl moiety and a 3’,4’,5’-trimethoxyanilino function at the 2- and 3-
position, respectively, of the thiophene ring fused with benzene or pyridine. 
Based on these observations, a new series of 2-alkoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino)thiophene derivatives with general formulae 4 was designed to 
explore the role of the benzene and pyridine portion of the benzo[b]thiophene and 
thieno[2,3-b]pyridine nucleus, respectively, in binding in the colchicine site of 
tubulin. We examined the replacement of benzo[b]thiophene and thieno[2,3-
b]pyridine bicyclic systems by a thiophene ring substituted at its 5-position with an 
aryl or heteroaryl moiety, whereas the 2-methoxycarbonyl group and the 3-(3,4,5-
trimethoxyanilino) function were kept unmodified.  
To evaluate the influence in the binding in the colchicine site of tubulin of the new 
structural modifications, preliminary docking studies were performed, following a 
previous reported method (22). The new derivatives occupy the active site in a 
similar manner as the co-crystallized DAMA-colchicine (Fig.3A: DAMA and 2-
methoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)-5-phenylthiophene derivative 4a), 
and their binding is consistent with the one reported previously for the thieno[2,3-
b]pyridine series (Fig.3B 4a and thieno[2,3-b]pyridine 3a). The trimethoxyphenyl 
ring is in proximity to Cys241, while the 5-phenyl ring is sitting deep in the small 
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hydrophobic pocket and potentially interacting with hydrophobic amino acids 
Met259, Thr314, Val181 and others. These interactions are similar to those modeled 
with the heterocycle of the thieno[2,3-b]pyridine series (Fig.3C compound 4a alone). 
Small substitutions on the 5-phenyl ring could be tolerated and did not affect the 
binding in a negative manner. As found previously for the benzo[b]thiophene and 
thieno[2,3-b]pyridine series, a molecular docking study revealed that the ortho-
relationship between the alkoxycarbonyl group and the 3,4,5-trimethoxyanilino 
moiety plays an important role in activity. This allows the formation of an 
intramolecular hydrogen bond between the hydrogen of the anilino group and the 
oxygen of carbonyl group, resulting in formation of a hydrogen bond between the 
ester itself and Ala250, further stabilizing these new compounds in the colchicine 
site. Encouraged by the activity obtained with compound 4a, we assessed the effects 
on biological activity of both the nature and position of electron-withdrawing (F, Cl, 
CF3 and NO2) and electron-releasing (CH3, OCH3 and OC2H5) substituents on the phenyl 
at the 5-position of 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene system 
as well as the replacement of the phenyl with the bioisosteric thien-2’-yl. 
A) B) C) 
Fig. 3 Proposed binding for compound 4a in comparison with DAMA-colchicine A) and 
derivative 3a B) in the colchicine site. Co-crystallized DAMA-colchicine is shown in green, 
compound 4a in magenta, and compound 3a in turquoise. The hydrophobic subpocket is 
highlighted with a turquoise surface. C)Proposed binding for compound 4a alone in the 
colchicine site. The hydrophobic subpocket is highlighted with a turquoise surface 
3.5.2 Chemistry 
2-Alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)-5-aryl/heteroaryl thiophene 
derivatives 4a-r were synthesized by a four step procedure summarized in Scheme 1. 
-Chloroaryl cinnamoniriles 6a-m were obtained by a modified Vilsmeier reaction of 
commercially available acetophenones 5a-m with phosphorus(V)oxychloride (POCl3) 
in dimethylformamide, followed by treatment with hydroxylamine hydrochloride 
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(NH2OH.HCl) (23). The subsequent condensation of compounds 6a-m with methyl or 
ethyl thioglycolate using sodium methoxide (MeONa) as base in a mixture of 
methanol/DMF furnished in mild conditions the corresponding 2-alkoxycarbonyl-3-
amino-5-aryl/heteroaryl thiophene derivatives 7a-r in good yields through the 
nucleophilic displacement of chlorine, followed by base-induced ring closure in a 
single step. Subsequent deaminative bromination using modified Sandmeyer 
conditions of 3-amino thiophenes 7a-r using tert-butyl nitrite (t-BuONO) in 
acetonitrile in the presence of copper(II)bromide (CuBr2) gave the target 
bromothiophene 8a-r in excellent yield. Finally, the novel derivatives 4a-r were 
obtained using Buchwald-Hartwig conditions, by coupling of bromide 8a-r with 3,4,5-
trimethoxyaniline in a palladium (II)acetate [Pd(OAc)2], 2,2-
bis(diphenylphosphino)1,1’-binaphthyl (BINAP) catalytic system in the presence of 
cesium carbonate (Cs2CO3) as base in toluene at 100°C for 18 h.  
 
Scheme 1 Reagents: a) POCl3, DMF then NH2OH.HCl; b: HSCH2CO2CH3 or HSCH2CO2C2H5, 
MeONa, MeOH/DMF, 60°C, 4 h; b) t-BuONO, CuBr2, CH3CN, 0°C then room temperature for 2 
h; c) 3,4,5-trimethoxyaniline, Pd(OAc)2, BINAP, Cs2CO3, PhMe, 100°C, 18 h. 
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3.5.3 In vitro antiproliferative activities  
Table 1 summarizes the antiproliferative effects of the 2-alkoxycarbonyl-3-anilino-5-
substituted thiophene derivatives 4a-r against the growth of murine leukemia 
(L1210), murine mammary carcinoma (FM3A/0), human T-lymphoblastoid leukemia 
(CEM) and human cervix carcinoma (HeLa) cells as compared with the reference 
compound CA-4. Comparing compounds which shared a common aryl moiety at the 5-
position of the of 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene scaffold, 
the 2-methoxycarbonyl derivatives were more potent than the 2-ethoxycarbonyl 
counterparts (4a, 4d, 4f, 4i, 4k versus 4b, 4e, 4g, 4j, 4l, respectively). Ignoring 
compound 4p, all synthesized compounds possessed significant cell growth inhibitory 
activity, which was lower than 1 M for compounds 4a, 4c-d, 4i-k, 4o and 4r in all 
cell lines. Hydrophobic moieties such as phenyl and thien-2’-yl were well tolerated at 
the 5-position of the 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene 
scaffold, and variation of the phenyl substituents had variable effects on potency. 
Replacement of the phenyl ring of compound 4a by the bioisosteric thien-2’ ring, to 
yield derivative 4c, increased antiproliferative activity 2-4-fold against L1210 and 
HeLa cells, while the two compounds showed comparable potency against FM3A and 
CEM cells. Of all the tested compounds, the thien-2’-yl derivative 4c possessed the 
highest overall cytostatic potency and inhibited the growth of the four cancer cell 
lines with IC50 values of 0.13-0.16 M, being 10- to 100-fold more active than the 
reference compound CA-4. Compound 4i was nearly as active as 4c. 
SAR was elucidated by substitution with electron-releasing and electron-withdrawing 
groups on the phenyl moiety at the 5-position of the 2-alkoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino)thiophene system. In general, single modification at the para-
position of the phenyl ring was well tolerated and para-substituted phenyl 
derivatives showed variable potencies, suggesting an opportunity for further 
exploration. In comparing the effect of electron releasing (ERG’s) or electron 
witwdrawing groups (EWG’s) at the para-position of the phenyl ring, in all cell lines 
compounds 4i and 4k with electron-donating methyl or methoxy groups, respectively, 
were generally more cytostatic than those with the electron-withdrawing fluoro or 
chloro moieties (derivatives 4d and 4f, respectively). The same effect was observed 
for the 2-ethoxycarbonyl derivatives (4j and 4l vs. 4e and 4g). Substituents at the 
para-position of the 5-phenyl ring showed antiproliferative activity in the order: 
Me>OMe>F>Cl=NO2>CF3>>OEt. 
3.ANTITUBULINIC AGENTS 
81 
Potency was reduced from 4- to 7-fold after the weak ERG p-methyl (4i) was 
replaced with the EWG trifluoromethyl in compound 4q. Turning to the effect of 
ERG’s on the phenyl moiety, with the exception of HeLa cells, we found that para-
tolyl and para-methoxyphenyl groups (compounds 4i and 4k, respectively) caused 
only minor changes in antiproliferative activity relative to the unsubstituted phenyl 
analogue 4a.  
Relative to the activity of the unsubstituted phenyl analogue 4a, the introduction of 
the EWG fluorine at the para-position of the phenyl ring (compound 4d) caused a 2-4-
fold reduction of antiproliferative activity in three of the four cancer cell lines. 
Increasing the size of the halogen from fluorine to chlorine (compounds 4d and 4f, 
respectively) reduced the activity on L1210 and CEM cells, while the two compounds 
were equipotent against FM3A and HeLa cell lines. While a single chlorine atom at 
the para-position of the phenyl group was tolerated for activity (4f), double 
substitution by the introduction of a second chlorine atom to furnish the meta, para-
dichlorophenyl derivative 4h caused a 4-5-fold reduction of potency relative to 4f in 
all cell lines. Replacement of the chlorine atom with even stronger EWG’s 
(trifluoromethyl or nitro; derivatives 4q and 4r, respectively) had generally little 
further effect on activity against the four cell lines.  
Replacement of the fluorine atom of 4d with the weak ERG methyl, resulting in para-
tolyl derivative 4i, increased antiproliferative activity by 3-4-fold against all cell 
lines, with potency similar to that of the thien-2’-yl analogue 4c.  
The number and location of methoxy substitutents on the phenyl ring played a 
profound role in antiproliferative activity. A comparison between the 
antiproliferative activities of compounds 4k and 4n-p, illustrated the 
antiproliferative SAR of the number of methoxy groups substituted on the phenyl ring 
(1>2>>3). The introduction of a single methoxy group at the para-position (compound 
4k) caused only minor changes in antiproliferative activity relative to the 
unsubstituted derivative 4a. Moving the methoxy group from the para- to the meta-
position, to furnish 4n, reduced antiproliferative activity 3-4-fold on three of the 
cancer cell lines. Reduced activity (2-fold) on three cancer cell lines relative to 4k 
occurred with the insertion of a second methoxy group, to furnish the meta, para-
dimethoxyphenyl analogue 4o, while activity was maintained against HeLa cells. This 
latter compound has antiproliferative activity similar to that of meta-methoxy 
analogue 4n against HeLa cells and increased potency against the three other cell 
lines. These results suggest that the optimal position for mono-methoxy substitution 
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is the para-position, as in compound 4k. Adding a third methoxy group, to yield 
derivative 4p, abolished antiproliferative activity.  
These results suggested that the space for accepting substituents on the phenyl at 
the 5-position of 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene system is 
highly limited and that the phenyl ring is specifically recognized by tubulin in a highly 
specific manner. In an effort to further understand the steric effect of the alkoxy 
substitution at the para-position of the phenyl ring, replacement of the para-
methoxy with a para-ethoxy homologue (compound 4m) resulted in a 5-20-fold 
reduction of cytostatic activity in all cell lines.  
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Table 1 In vitro inhibitory effects of compounds 4a-r and CA-4 against the proliferation of 
murine leukemia (L1210), murine mammary carcinoma (FM3A), human T-lymphocyte leukemia 
(CEM) and human cervix carcinoma (HeLa) cells 
Compounds 
IC50 μM 
L1210 FM3A/0 CEM HeLa 
4a 0.24 ± 0.01 0.21 ± 0.03 0.20 ± 0.08 0.67 ± 0.40 
4b 1.1 ± 0.0 0.98 ± 0.13 0.93 ± 0.08 1.4 ± 0.7 
4c 0.13 ± 0.07 0.16 ± 0.01 0.16 ± 0.08 0.16 ± 0.02 
4d 0.56 ± 0.38 0.72 ± 0.19 0.53 ± 0.38 0.88 ± 0.16 
4e 1.1 ± 0.0 1.0 ± 0.2 0.99 ± 0.24 2.1 ± 1.1 
4f 1.1 ± 0.1 0.88 ± 0.08 0.87 ± 0.18 0.87 ± 0.13 
4g 6.0 ± 0.0 5.1 ± 0.5 4.6 ± 0.6 9.8 ± 5.0 
4h 5.7 ± 0.1 4.6 ± 0.6 3.3 ± 1.7 5.0 ± 1.3 
4i 0.15 ± 0.08 0.18 ± 0.01 0.18 ± 0.04 0.26 ± 0.10 
4j 0.82 ± 0.31 0.82 ± 0.23 0.76 ± 0.38 0.78 ± 0.06 
4k 0.27 ± 0.03 0.25 ± 0.04 0.23 ± 0.10 0.84 ± 0.10 
4l 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.3 2.3 ± 1.5 
4m 6.3 ± 0.0 5.7 ± 0.5 5.4 ± 1.3 4.4 ± 0.2 
4n 1.1 ± 0.1 0.99 ± 0.10 0.69 ± 0.46 0.80 ± 0.06 
4o 0.48 ± 0.27 0.43 ± 0.29 0.47 ± 0.35 0.89 ± 0.08
4p >250 >250 >250 162 ± 25 
4q 1.2 ± 0.1 1.1 ± 0.1 0.81 ± 0.33 1.3 ± 0.2 
4r 0.99 ± 0.13 0.93 ± 0.08 0.76 ± 0.21 1.0 ± 0.3 
CA-4 (nM) 3 ± 1 42 ± 6 2 ± 1 2 ± 1 
IC50 = compound concentration required to inhibit tumour cell proliferation by 50%. Data are 
expressed as the mean ± SD from three independent experiments 
3.5.4 Evaluation of cytotoxicity of 4a, 4c and 4i compounds in human 
noncancer cells 
To obtain a preliminary indication of the cytotoxic potential of these derivatives in 
normal human cells, three of the most active compounds (4a, 4c and 4i) were 
evaluated in vitro against peripheral blood lymphocytes (PBL) from healthy donors 
(Table 2). All compounds were practically devoid of a significant citotoxic activity in 
quiescent lymphocytes being the GI50 in the range of 30-85 µM, while in the presence 
of the mitogenic stimulus phytohematoaglutinin (PHA), the GI50 slightly increase to 
about 20-30 µM. 
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Nevertheless, these values, even in proliferation conditions, are more than 100 times 
that found in the two lines of T lymphoblastic leukemia (L1210 and CEM) reported in 
Table 2. These results indicate that these compounds are endowed with a very 
modest effect in rapidly proliferating cells but not in quiescent cells.  
Table 2. Cytotoxicity of compounds 4a, 4c and 4i for human peripheral blood lymphocytes 
(PBL) 
 GI50 (µM) a 
 4a 4c 4i 
PBLrestingb 45.7 ± 10.9 85.7 ± 8.9 31.7 ± 2.0 
PBLPHAc 19.0 ± 1.7 29.3 ± 1.2 20.0 ± 1.1 
aCompound concentration required to reduce cell growth inhibition by 50%. 
b PBL not stimulated with PHA. 
c PBL stimulated with PHA. 
Values are the mean ± SEM from two separate experiments. 
3.5.5 Inhibition of tubulin polymerization and colchicine binding  
To investigate whether the activities of these molecules were related to an 
interaction with the microtubule system, the more active compounds (4a, 4c-d, 4i, 
4k and 4o) and reference compound CA-4 were evaluated for their in vitro tubulin 
polymerization inhibitory activity as well as for their inhibitory effects on the binding 
of [3H]colchicine to tubulin (in the latter assay, the compounds and colchicine were 
at 5 M, and tubulin was at 1 µM) (Table 3). In the tubulin polymerization assay, 
these compounds showed IC50 values in a relatively narrow range (1,2-2,7 M). Three 
compounds (4a, 4c and 4i) showed the best tubulin polymerization assembly 
inhibition ability (IC50: 1,2-1,3 M), which is comparable to the IC50 of 1,1 µM 
obtained with CA-4, while derivatives 4d, 4k and 4o were about half as potent as CA-
4. Derivatives 4a, 4c and 4i also displayed the most potent activities against the 
panel of four cancer cell lines. The results obtained demonstrated that 
antiproliferative activity correlated well with inhibition of tubulin polymerization.  
In the colchicine binding studies, compounds 4a, 4c and 4i were also the best 
inhibitors of the binding of [3H]colchicine to tubulin. None, however, was quite as 
potent as CA-4, which in these experiments inhibited colchicine binding by 99%. The 
potent inhibition observed with these compounds indicated that 4a, 4c and 4i bind to 
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tubulin at a site overlapping the colchicine site. This group of compounds were all 
highly potent in the biological assays (inhibition of cell growth, tubulin assembly and 
colchicine binding), and there was a good correlation between the three assay types. 
We conclude that the antiproliferative activity of these derivatives derives from an 
interaction with the colchicine site of tubulin and interference with cellular 
microtubule assembly.  
Table 3 Inhibition of tubulin polymerization and colchicine binding by compounds 4a, 4c-d, 
4i, 4k, 4o and CA-4. 
Compound 
Tubulin assemblya 
IC50 ± SD (M) 
Colchicine bindingb 
% ± SD 
4a 1.3 ± 0.2 57 ± 5 
4c 1.2 ± 0.1 62 ± 1 
4d 2.2 ± 0.3 41 ± 5 
4i 1.2 ± 0.0 70 ± 3 
4k 2.0 ± 0.3 46 ± 4 
4o 2.7 ± 0.0 30 ± 3 
CA-4 1.1 ± 0.1 99 ± 3 
A)Inhibition of tubulin polymerization. Tubulin was at 10 M; b) inhibition of [3H]colchicine 
binding. Tubulin, colchicine and tested compound were at 1, 5 and 5 M, respectively. 
3.5.6 Effects of 4a, 4c and 4i on the cell cycle  
The effect of compounds 4a, 4c and 4i on cell cycle progression was examined by 
flow cytometry in Hela cells. After a 24 h treatment (Fig.4), the three compounds 
induced a G2-M arrest that became evident at the highest concentration used (500 
nM). A concomitant reduction of cells in the G1 phase was also observed, while S 
phase cells remained essentially constant, although there was a slight increase in S 
phase cells that occurred at 500 nM with all compounds.  
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Fig. 4 Compounds 4a, 4c, 4i induce G2-M arrest in Hela cells. Percentage of cells in each 
phase of the cell cycle in HeLa cells, treated with compounds 4a (A), 4c (B) and 4i (C) at the 
indicated concentrations for 24 h. Cells were fixed and labeled with PI and analyzed by flow 
cytometry as described in the Experimental Section. Data are presented as mean of two 
independent experiments ± SEM. 
We also studied the association between 4c-induced G2-M arrest and alterations in 
G2-M regulatory protein expression in HeLa cells. As shown in Fig.5, compound 4c 
caused, in a concentration-dependent manner, an increase in cyclin B1 expression 
after 24 h, followed by a marked reduction at 48 h, indicating an activation of the 
mitotic checkpoint following drug exposure (24). This effect was confirmed by a 
remarkable reduction in the expression of phosphatase cdc25c after a 24 h 
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incubation, even at the lowest concentration used (100 nM). The phosphorylation of 
cdc25c directly stimulates its phosphatase activity, and this is necessary to activate 
cdc2(CDK1)/cyclin B on entry into mitosis (25). Accordingly, we observed a decrease 
in the phosphorylated form of cdc2 (CDK1) kinase after 24 h and 48 h treatments at 
250 nM. 
 
Fig. 5 Effect of compound 4c on cell cycle checkpoint proteins. HeLa cells were treated for 
24 or 48 h with the indicated concentrations of 4c. The cells were harvested and lysed for 
detection of the expression of the indicated proteins by western blot analysis. To confirm 
equal protein loading, each membrane was stripped and reprobed with anti--actin antibody. 
3.5.7 Compounds 4a, 4c and 4i induce apoptosis  
To evaluate the mode of cell death, we treated HeLa cell with compounds 4a, 4c and 
4i, and, after 24 and 48 h incubations, we performed a biparametric cytofluorimetric 
analysis using propidium iodide (PI) and annexin-V-FITC, which stain DNA and 
phosphatidylserine (PS) residues, respectively. As shown in Fig.6, the three 
compounds induced a significant proportion of apoptotic cells after the 24 h 
incubation, and this proportion increase markedly at 48 h. The most active 
compounds appear to be 4c and 4i, in good agreement with the antiproliferative 
results presented in Table 1.  
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Fig. 6 Flow cytometric analysis of apoptotic cells after treatment of HeLa cells with 4a (A), 
4c (B) and 4i (C) at the indicated concentrations after incubation for 24 or 48 h. The cells 
were harvested and labeled with annexin-V-FITC and PI and analyzed by flow cytometry. Data 
are presented as mean ± SEM of three independent experiments. 
3.5.8 Compound 4c induces mitochondrial depolarization and ROS production 
It is well known that mitochondria are involved in the initiation of apoptosis, since, 
at an early stage, apoptotic stimuli alter the mitochondrial transmembrane potential 
(mt) (26,27). To determine whether the cells treated with compound 4c underwent 
mitochondrial depolarization, we assessed the changes in mt in HeLa cells by flow 
cytometry using the fluorescent dye JC-1. HeLa cells treated with compound 4c (100-
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250 nM) showed a time-dependent increase in the percentage of cells with low mt 
(Fig.7A). The depolarization of the mitochondrial membrane is associated with the 
appearance of annexin-V positivity in the treated cells when they are in an early 
apoptotic stage (28). One of the major consequences of the increase of 
mitochondrial membrane permeability is the release into the cytosol of pro-apoptotic 
factors such as procaspases and, in particular, cytochrome c (29) This release triggers 
ROS production at the mitochondrial level during the later stages of the cell death 
program. We therefore investigated whether ROS production increased after 
treatment with compound 4c. We analyzed ROS production by flow cytometry, using 
the fluorescence indicator H2-DCFDA. As shown in Fig.7B, compound 4c induced 
significant production of ROS starting after a treatment of 12-24 h at 250 nM, in good 
agreement with the mitochondrial depolarization described above. 
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Fig. 7 Compound 4c induces 
mitochondrial depolarization and ROS 
production.  
(A) Hela cells were treated with the 
indicated concentration for 6, 12, 24 or 
48 h and then stained with the 
fluorescent probe JC-1 for analysis of 
mitochondrial potential. Cells were 
then analyzed by flow cytometry as 
described in the experimental section. 
Data are presented as mean ± SEM of 
three independent experiments. 
 (B) Cells were treated with the 
indicated concentration for 6, 12, 24 or 
48 h and then stained with H2-DCFDA 
for evaluation of ROS levels. Cells were 
then analyzed by flow cytometry as 
described in the Experimental Section. 
Data are presented as mean ± SEM of 
three independent experiments.  
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3.5.9 Compound 4c induced PARP activation and decreased expression of anti 
apoptotic proteins 
To further investigate the mechanism of apoptosis induction by 4c, we analyzed the 
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expression of poly (ADP-Ribose) polymerase (PARP), a protein involved in late stage 
apoptosis, and the expression of two anti-apoptotic proteins belonging to the Bcl-2 
family. As shown in Fig.8, compound 4c in HeLa cells caused a concentration- and 
time-dependent cleavage of PARP confirming the pro-apoptotic properties of 4c. 
We also investigated the expression of anti-apoptotic proteins such as Bcl-2 and Mcl-
1. It is well known that antimitotic agents can modulate both expression levels and 
activity of many proteins of the Bcl-2 family (30, 31, 32) Our results (Fig.8) showed 
that the expression of both anti-apoptotic proteins Bcl-2 and Mcl-1 were decreased 
starting after 24 h of treatment, even at the lowest 4c concentration used (0.1 M). 
These studies underline the importance of Mcl-1 phosphorylation and its subsequent 
degradation in response to antimitotic agents and that this event potentiates cell 
death (33). 
Fig. 8 Western blot analysis of, Bcl-2, Mcl-1 and PARP after treatment of HeLa cells with 4c 
at the indicated concentrations and times. To confirm equal protein loading, each membrane 
was stripped and reprobed with anti--actin antibody. 
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3.6 Discussion 
We have discovered a new class of simple synthetic inhibitors of tubulin 
polymerization based on the molecular skeleton of 2-alkoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino)thiophene. These derivatives were designed and synthesized based 
on modification of benzo[b]thiophene and thieno [2,3-b]pyridine analogues 
previously published. The results demonstrated that the aryl or 2-thienyl moieties at 
the 5-position of the 2-alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene 
system could replace either the benzene or the pyridine portion of 
benzo[b]thiophene and thieno [2,3-b]pyridine derivatives with general structure 2 
and 3, respectively. We explored SAR by examining various substitutions with EWGs 
and ERGs on the phenyl at the 5-position of the 2-alkoxycarbonyl-3-(3’,4’,5’-
trimethoxyanilino)thiophene scaffold. The presence of ERGs such as methyl or 
methoxy was beneficial for antiproliferative activity, as these compounds proved to 
be more potent than the corresponding derivatives with the EWGs fluorine or 
chlorine. Generally, it was found that most substituents in the para-position resulted 
in lower activity as compared to the unsubstituted parent compound 4a, with the 
least deleterious being methyl and methoxy moieties (compounds 4i and 4k, 
respectively).  
It is clear that the substitution pattern on the phenyl at the 5-position of the 2-
methoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene system plays an important 
role for antitubulin and antiproliferative activities, and this was supported by the 
molecular docking studies. SAR studies showed that the 2-methoxycarbonyl-3-
(3’,4’,5’-trimethoxyanilino)-5-phenylthiophene derivative 4a, its bioisosteric thien-
2’-yl analogue 4c as well as the para-tolyl and para-methoxyphenyl analogues 4i and 
4k, respectively, displayed high antiproliferative activities, with IC50 values 0.13-
0.24, 0.16-0.25, 0.16-0.23 and 0.16-0.84 M, respectively, against the L1210, FM3A, 
CEM and HeLa cell lines. Of all the tested compounds, derivative 4c possessed the 
highest overall cytostatic potency with IC50 values ranging from 0.13 to 0.16 M 
against the panel of four cancer cell lines. The antiproliferative activity was 
considerably increased by replacing the EWG fluorine with the ERG methyl group 
(compounds 4d and 4i, respectively), with the latter compound being about 3-6-fold 
more active than the former. By comparing 4d and 4f, replacement of the para-
fluoro group in 4d with the chloro (derivative 4f) led to little change in activity 
against FM3A and HeLa cells, while 4f was less potent than 4d in L1210 and CEM 
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cells. Replacement of the EWG para-chlorine atom of 4f with the ERG para-methyl 
moiety, to furnish derivative 4i, resulted in 4-6-fold enhancement in antiproliferative 
activity against the four cancer cell lines. Replacement of the methyl with a methoxy 
group (derivative 4k) produced a 2- and 3-fold reduction in potency against L1210 
and HeLa cells, respectively, while the difference between 4i and 4k were minimal 
in FM3A and CEM cells.  
The antiproliferative activity of the thiophene derivatives 4k and 4n-p can be further 
characterized in terms of the substitution pattern and the number of methoxy groups 
on the phenyl ring. The introduction of a single methoxy group at the para-position 
caused only minor changes in antiproliferative activity relative to the unsubstituted 
derivative 4a. Reduced activity occurred in three of the four cancer cell lines when 
the methoxy substituent was moved from the para- to the meta-position (4n), with 
the exception of HeLa cells. As previously observed comparing the activities of para-
chloro and meta, para-dichloro derivatives 4f and 4h, respectively, the introduction 
of a second methoxy group at the meta-position of para-methoxyphenyl derivative 
4k, to furnish the meta, para-dimethoxyphenyl analogue 4o, decreased potency in 
three of the four cancer cell lines by 2-fold, with the exception of the HeLa cells. 
The 3’,4’,5’-trimethoxyphenyl derivative 4p was not active, and this result suggested 
the space for accepting substituents on the phenyl ring at the 5-position of the 2-
alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)thiophene scaffold is highly limited. 
This conclusion was supported by comparing the reduced activity (on average 20-
fold) of the para-ethoxy homologue 4m relative to the para-methoxy analogue 4k.  
The results we obtained indicated that compound 4c could induce tumour cell 
apoptosis through reducing the mitochondrial membrane potential and regulating the 
expression of apoptosis-related proteins in tumour cells. 
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